

## Full-length review

## Pathophysiology of perinatal brain damage

Richard Berger <sup>\*</sup>, Yves Garnier*Department of Obstetrics and Gynecology, University of Bochum, Bochum, Germany*

Accepted 4 May 1999

---

**Abstract**

Perinatal brain damage in the mature fetus is usually brought about by severe intrauterine asphyxia following an acute reduction of the uterine or umbilical circulation. The areas most heavily affected are the parasagittal region of the cerebral cortex and the basal ganglia. The fetus reacts to a severe lack of oxygen with activation of the sympathetic–adrenergic nervous system and a redistribution of cardiac output in favour of the central organs (brain, heart and adrenals). If the asphyxic insult persists, the fetus is unable to maintain circulatory centralisation, and the cardiac output and extent of cerebral perfusion fall. Owing to the acute reduction in oxygen supply, oxidative phosphorylation in the brain comes to a standstill. The  $\text{Na}^+/\text{K}^+$  pump at the cell membrane has no more energy to maintain the ionic gradients. In the absence of a membrane potential, large amounts of calcium ions flow through the voltage-dependent ion channel, down an extreme extra-/intracellular concentration gradient, into the cell. Current research suggests that the excessive increase in levels of intracellular calcium, so-called calcium overload, leads to cell damage through the activation of proteases, lipases and endonucleases. During ischemia, besides the influx of calcium ions into the cells via voltage-dependent calcium channels, more calcium enters the cells through glutamate-regulated ion channels. Glutamate, an excitatory neurotransmitter, is released from presynaptic vesicles during ischemia following anoxic cell depolarisation. The acute lack of cellular energy arising during ischemia induces almost complete inhibition of cerebral protein biosynthesis. Once the ischemic period is over, protein biosynthesis returns to pre-ischemic levels in non-vulnerable regions of the brain, while in more vulnerable areas it remains inhibited. The inhibition of protein synthesis, therefore, appears to be an early indicator of subsequent neuronal cell death. A second wave of neuronal cell damage occurs during the reperfusion phase. This cell damage is thought to be caused by the post-ischemic release of oxygen radicals, synthesis of nitric oxide (NO), inflammatory reactions and an imbalance between the excitatory and inhibitory neurotransmitter systems. Part of the secondary neuronal cell damage may be caused by induction of a kind of cellular suicide programme known as apoptosis. Knowledge of these pathophysiological mechanisms has enabled scientists to develop new therapeutic strategies with successful results in animal experiments. The potential of such therapies is discussed here, particularly the promising effects of i.v. administration of magnesium or post-ischemic induction of cerebral hypothermia. © 1999 Elsevier Science B.V. All rights reserved.

**Keywords:** Perinatal; Brain damage; Post-ischemic

---

**Contents**

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| 1. Introduction . . . . .                                         | 108 |
| 2. Causes of hypoxic–ischemic brain lesions in neonates . . . . . | 108 |
| 3. Circulatory centralisation and cerebral perfusion . . . . .    | 108 |
| 4. Neuropathology of hypoxic–ischemic brain lesions . . . . .     | 110 |
| 5. Energy metabolism and calcium homeostasis . . . . .            | 112 |
| 6. Excitatory neurotransmitters . . . . .                         | 113 |

---

<sup>\*</sup> Corresponding author. Universitäts-Frauenklinik, Knappschafts Krankenhaus, In der Schornau 23–25, 44982 Bochum, Germany. Fax: +49-234-299-3309; E-mail: richard.berger@ruhr-uni-bochum.de

|                                                            |     |
|------------------------------------------------------------|-----|
| 7. Protein biosynthesis . . . . .                          | 115 |
| 8. Secondary cell damage during reperfusion . . . . .      | 116 |
| 8.1. Oxygen radicals . . . . .                             | 116 |
| 8.2. NO . . . . .                                          | 116 |
| 8.3. Inflammatory reactions . . . . .                      | 118 |
| 8.4. Glutamate . . . . .                                   | 118 |
| 9. Apoptosis and post-ischemic genome expression . . . . . | 119 |
| 10. Therapeutic strategies . . . . .                       | 121 |
| 10.1. Hypothermia . . . . .                                | 121 |
| 10.2. Pharmacological intervention . . . . .               | 123 |
| 10.3. Magnesium . . . . .                                  | 123 |
| 11. Conclusion . . . . .                                   | 125 |
| References . . . . .                                       | 125 |

## 1. Introduction

Year after year, around a thousand children in Germany alone incur brain damage as a result of a perinatal hypoxic–ischemic insult ([249], Perinatal statistics for the Federal Republic of Germany). Depending on the extent and location of the insult these children can develop spastic paresis, choreo-athetosis, ataxia and disorders of sensorimotor coordination (Fig. 1). Nor is it uncommon for damage to the auditory and visual systems and impairment of intellectual ability to develop later [339]. The resulting impact on the children affected and their families is considerable and their subsequent care demands a high level of commitment and co-operation between pediatricians, child neurologists, physio-, speech-, and psychotherapists and other specialists. Conservative estimates of the costs to society for treatment and care of such cases per birth year lie around 1 billion German marks. However, despite the severe clinical and socio-economic significance, no effective therapeutic strategies have yet been developed to counteract this condition; one possible explanation being that perinatal management up to now has focused on preventing hypoxic–ischemic brain damage altogether [339]. The pathophysiology of ischemic brain lesions has not been investigated in depth until recently. One of the most urgent tasks for obstetricians and neonatologists will now be to develop therapeutic strategies from these pathophysiological models and to test them in prospective clinical studies.

This review article presents our current understanding of the pathophysiology of hypoxic–ischemic brain damage in mature neonates. The situation in premature neonates is discussed separately wherever necessary. We first deal with the causes of ischemic brain lesion, especially intrauterine asphyxia of the fetus, and their effects on the cardiovascular system and cerebral perfusion. Next, the

typical neuropathological findings arising from reduced perfusion of the fetal brain are described. Also of key importance are the cellular mechanisms that are triggered by an ischemic insult. These will be discussed in detail, with particular emphasis on alterations of energy metabolism, intracellular calcium accumulation, the release of excitatory amino acids and protein biosynthesis. A considerable portion of neuronal cell damage first occurs during the reperfusion phase following an ischemic insult. The formation of oxygen radicals, induction of the NO system, inflammatory reactions and apoptosis will therefore be discussed in depth in this context. Finally, therapeutic concepts will be presented that have developed out of our understanding of these pathophysiological processes and been tested in animal experiments. Of these, i.v. administration of magnesium and induction of cerebral hypothermia appear to be of the greatest clinical relevance.

## 2. Causes of hypoxic–ischemic brain lesions in neonates

With a few exceptions, acute hypoxic–ischemic brain lesions in neonates are caused by severe intrauterine asphyxia [339]. This is usually brought about by an acute reduction in the uterine or umbilical circulation (Review: Ref. [157]), which in turn can be caused by abruptio placentae, contracture of the uterus, vena cava occlusion syndrome, compression of the umbilical cord, etc. (Table 1).

## 3. Circulatory centralisation and cerebral perfusion

The fetus reacts to an oxygen deficit of this severity by activating the sympathetic–adrenergic system and redistributing the cardiac output in favour of the central organs




Fig. 1. Spastic diplegia in children with cerebral palsy [51].

(brain, heart and adrenals) (Review: Ref. [157]). The lowered oxygen and raised carbon dioxide partial pressures lead to vasodilatation of the cerebral vascular bed [163,172] causing cerebral hyperperfusion. This affects the brainstem

Table 1  
Causes of severe intrauterine asphyxia

(I) *Uteroplacental unit*

- Contracture of the uterus
- Vena-cava-occlusion syndrome
- Hypotension
- Placenta praevia
- Abruptio placentae

(II) *Umbilical vessels*

- Compression of umbilical vessels
- Insertio velamentosa

in particular, while the blood flow to the white matter of the brain is hardly increased at all (Refs. [12,164,196], Review: Ref. [157]). Depending on the extent of the oxygen deficit and the maturity of the fetus, this cerebral hyperperfusion can reach two to three times the original rate of blood flow. Paradoxically, complete arrest of uterine perfusion is found to cause an initial reduction of blood flow to the brain [156]. If the oxygen deficit persists, the anaerobic energy reserves of the heart become exhausted. The cardiac output and the mean arterial blood pressure fall [289]. At mean arterial blood pressures of below 25–30 mmHg, there is an increasing loss of cerebral autoregulation, and a consequent reduction of the cerebral blood flow [195]. This affects the parasagittal region of the cerebrum [276] and the white matter [59,316] most of all. Immature fetuses seem to be particularly endangered by their limited ability to increase blood flow to the white matter through vasodilatation [316].




Fig. 2. Blood flow to the cerebrum ((ml/min) × 100 g) in fetal sheep near term before, during, and after global cerebral ischemia of 30-min duration. Cerebral ischemia was induced by occluding both carotid arteries. Results are given as mean ± S.D. The data were analysed for intragroup differences by multivariate analysis of variance for repeated measures. Games–Howell-test was used as post-hoc testing procedure (\*\*  $P < 0.01$ , \*\*\*  $P < 0.001$  (ischemia/recovery vs. control)) [33,39].

If the supply of oxygen to the fetus can be improved, cerebral hyperperfusion is brought about by the progressive post-asphyxial increase in cardiac output (Ref. [282], Review: Ref. [157]). This hyperperfusion can also be demonstrated in experiments using animal models of isolated cerebral ischemia (Fig. 2) [33]. Vasodilatation induced by acidosis in cerebral tissues and a reduction of blood viscosity at higher rates of blood flow have been put forward as possible causes of such hyperperfusion [182,293,317]. The initial hyperperfusion of the brain is followed directly by a phase of hypoperfusion (Fig. 2) [33,283]. Surprisingly, the shorter the duration of ischemia, the more marked this hypoperfusion appears to be. Post-ischemic hypoperfusion is characterised by a dissociation of the disturbed  $\text{CO}_2$ -reactivity from autoregulation of the cerebral vascular bed which remains intact. This leads to vasoconstriction and an uncoupling of blood flow and metabolic activity (Review: Ref. [147,302]). Post-ischemic hypoperfusion may be caused by oxygen radicals formed during the reperfusion phase after ischemia. Rosenberg et al. demonstrated that this phenomenon can be prevented by inhibiting the synthesis of oxygen radicals after ischemia [283]. In addition, a so-called no-reflow phenomenon can be observed after severe cerebral ischemia [8]. This failure of reperfusion in various brain areas is a consequence of the greater viscosity of stagnant blood, compression of the smallest blood vessels through swelling of the perivascular glial cells, formation of endothelial microvilli, increased intracerebral pressure, post-ischemic arterial hypotension and increased intravascular coagulation. The extent of the

no-reflow phenomenon depends on the duration and type of cerebral ischemia. It is most pronounced when the vessels are engorged with blood after venous congestion (Review: Ref. [147]). Directly after post-ischemic hypoperfusion, the cerebral blood flow recovers or overshoots into a second phase of hyperperfusion (Fig. 2) [33,271]. Since this hyperperfusion is often accompanied by an isoelectric encephalogram, it is regarded as an extremely unfavourable prognostic factor [271].

#### 4. Neuropathology of hypoxic–ischemic brain lesions

There are essentially six forms of hypoxic–ischemic brain lesion (Table 2): selective neuronal cell damage, status marmoratus, parasagittal brain damage, periventricular leucomalacia, intraventricular or periventricular haemorrhage and focal or multifocal ischemic brain lesions (Table 2) [102,339].

In mature fetuses, selective neuronal cell damage is found most frequently in the cerebral cortex, hippocampus, cerebellum and the anterior horn cells of the spinal cord [96,179,241,279,310,339]. As shown in animal experiments, the damage occurs after ischemia of only 10 min [351]. Within the cortex, the border zones between the major cerebral arteries are the worst affected. The cell damage is mostly parasagittal and more marked in the sulci than in the gyri, i.e., the pattern of distribution is strongly dependent on perfusion. The neurons show the most damage while the oligodendrocytes, astroglia and microglia remain largely unscathed (Review: Ref. [339]).

Status marmoratus, which is observed in only 5% of children with hypoxic–ischemic brain lesions, chiefly affects the basal ganglia and the thalamus. The complete picture of the disease does not emerge until 8 months after birth although the insult begins to take effect during the perinatal period. Status marmoratus is characterised by loss

Table 2

Hypoxic–ischemic brain damage in the fetus and neonate

| Neurologic lesion                         | Topographic localization                                                              |
|-------------------------------------------|---------------------------------------------------------------------------------------|
| Selective neuronal necrosis               | cortex cerebri<br>cerebellum<br>hippocampus<br>anterior horn cells of the spinal cord |
| Status marmoratus                         | basal ganglia<br>thalamus                                                             |
| Parasagittal cerebral injury              | cortex cerebri and subcortical<br>substantia alba                                     |
| Periventricular leucomalacia              | substantia alba                                                                       |
| Intra-, periventricular hemorrhage        | germinal matrix<br>substantia alba<br>ventricles                                      |
| Focal/multifocal ischemic<br>Brain damage | cortex cerebri and subcortical<br>substantia alba                                     |

of neurones, gliosis and hypermyelination. The increased number of myelinated astrocytic cell processes and their abnormal distribution give the structures affected, especially the putamen, a marbled appearance [96,279,280].

Parasagittal brain damage caused by cerebral ischemia is mostly reported in mature neonates [96,179,241,279,310,339] and affects the parietal and occipital regions in particular. The damage usually arises through insufficient perfusion of the border zones between the main cerebral arteries during cerebral ischemia. This form of damage has been reproduced in animal models (Fig. 3). The extent of the brain lesions was found to be closely dependent on the duration and severity of the cerebral ischemia [33,351]. Interestingly, in the cortex, sulci are more badly damaged than the gyri. This arises from the special way in which the blood vessels in the cortex and surrounding white matter develop. When the sulci take shape and deepen in mature neonates, the penetrating blood vessels branching out from the meningeal arteries are forced into a hairpin bend as they cross the border from grey matter into white matter [79]. This produces a triangular area within the white matter at the base of the sulci through which hardly any vessels pass. Thus, any reduction in the perfusion of this region causes most damage to the sulci of the cortex

[79,318]. This pattern of damage seems to correspond to that observed clinically in cases of subcortical leucomalacia [149,331].

Periventricular leucomalacia is characterised by damage to the white matter dorsal and lateral to the lateral ventricle [179,241]. It occurs most frequently in immature fetuses and chiefly affects the radiatio occipitalis at the trigonum of the lateral ventricle and the white matter around the foramen of Monro. At 6–12 h after an ischemic insult, necrotic foci can be observed in these areas [15]. These are characterised by swelling and rupture of neuronal axons. Necrotic oligodendrocytes are also found, especially ones undergoing differentiation or taking part in myelination. Over the next 24 to 48 h, activated microglia are seen more and more frequently. In 25% of cases, periventricular leucomalacia is accompanied by parenchymatous haemorrhaging [11,80,261]. As the disease progresses, small cysts develop out of the necrotic foci that can be identified by ultrasonography [81,144,261]. As gliosis progresses the cysts begin to constrict. The lack of myelination owing to the destruction of the oligodendrocytes and an enlargement of the lateral ventricle then become the most prominent features of the disease [75,280,318,319]. Periventricular leucomalacia around the radiatio occipitalis at the trigonum of the lateral ventricle and in the white matter around the foramen of Monro arises through vascular problems. Especially in immature fetuses, the ability to increase blood flow by vasodilatation during and after a period of arterial hypotension appears to be extremely limited in these brain areas [316]. After the 32nd week of pregnancy the vascularisation of these vulnerable areas is considerably increased and the incidence of periventricular leucomalacia thereby reduced.

Intra- or periventricular haemorrhage is another typical lesion of the immature neonate brain [339]. It originates in the vascular bed of the germinal matrix, a brain region that gradually shrinks until it has almost completely disappeared in the mature fetus [79,131,180,231,235,315]. Blood vessels in this brain region burst very easily [176,262]. Sub- and post-partum fluctuations in cerebral blood flow can therefore lead to rupture of these vessels causing intra- or periventricular haemorrhage [34,97,107,143,158,206,221]. The bleeding is sometimes exacerbated by factors affecting the aggregation of thrombocytes or the coagulating process [7,198,299]. Possible consequences of a brain haemorrhage are destruction of the germinal matrix, a periventricular haemorrhagic infarction in the cerebral white matter or hydrocephalus (Review: Ref. [339]).

Focal or multifocal brain damage usually occurs within areas supplied by one or more of the main cerebral arteries. This form of insult is not normally observed before the 28th week of pregnancy. The incidence then rises with increasing maturity of the fetus [17]. Histologically, it is an infarct involving all types of cells (neurones, oligodendrocytes, astrocytes and endothelial cells). In the days following an insult, microglia and astrocytes migrate into the




Fig. 3. Neuronal cell damage in the cerebrum of fetal sheep near term 72 h after induction of global cerebral ischemia of 30-min duration. Cerebral ischemia was induced by occluding both carotid arteries. Neuronal cell damage was quantified as follows: 0–5% damage (score 1), 5–50% damage (score 2), 50–95% damage (score 3), 95–99% damage (score 4), and 100% damage (score 5). Neuronal cell damage was most pronounced in the parasagittal regions, whereas in the more lateral part of the cortex only minor neuronal damage occurred. There was a tremendous reduction in neuronal cell damage after pre-treatment with the calcium antagonist flunarizine (1 mg/kg estimated fetal body weight), whereas glutamate antagonist lubeluzole failed to protect the fetal brain. Values are given as mean  $\pm$  S.D. The data were analysed within and between groups using a two-way ANOVA followed by Games–Howell post-hoc test (\* $P < 0.05$ , \*\* $P < 0.01$  (treated vs. untreated)) [39,98].

Table 3

Concentrations of high-energy phosphates in the cerebral cortex of fetal guinea pigs near term during acute asphyxia caused by arrest of uterine blood flow [27,28]. Values are given as mean  $\pm$  S.D.

|                         | Brain metabolite [ $\mu$ mol/g] |                   |                   |
|-------------------------|---------------------------------|-------------------|-------------------|
|                         | Control                         | Asphyxia (2 min)  | Asphyxia (4 min)  |
| Adenosine triphosphate  | 2.59 $\pm$ 0.15                 | 2.03 $\pm$ 0.21** | 1.35 $\pm$ 0.32** |
| Adenosine diphosphate   | 0.37 $\pm$ 0.07                 | 0.76 $\pm$ 0.13** | 1.05 $\pm$ 0.15** |
| Adenosine monophosphate | 0.04 $\pm$ 0.02                 | 0.17 $\pm$ 0.09** | 0.52 $\pm$ 0.21** |

\*\* $P < 0.01$  (asphyxia vs. control).

infarct zone [96,181,204,242,243,277]. The infarct is usually caused by arterial embolism or venous thrombosis. In 90% of the cases, the arterial occlusion is unilateral and mainly involves the left arteria cerebri media (Refs. [153,298,328], Review: Ref. [339]). Unlike the situation in the mature brain, this form of brain infarct leaves no scar tissue but often produces one or more cysts. They occur as a result of the high water content of the immature brain, an insufficient ability to myelinate and an inadequate astrocytic response to an ischemic insult. The scar-like structures running across the infarcted area are seldom pronounced in immature brain tissue. Thus, the morphological changes brought about by an ischemic insult also vary depending on the maturity of the brain [161,339]. Focal or multifocal brain lesions following infections, trauma or twin births, especially monochorionic ones, are also relatively common [22,25,46,268,291,356]. It is thought that

thromboplastic material or emboli from a miscarried co-twin sometimes occludes the cerebrovascular circulation of the living twin. Brain damage may also be caused by anemia or polycythemia and subsequent cardiac insufficiency and cerebral hypoperfusion arising from a feto-fetal transfusion. Alternatively, focal or multifocal brain damage can arise from systemic arterial hypotension, so that there is little distinction between this and other forms of brain damage such as selective neuronal cell damage, status marmoratus, parasagittal brain damage or periventricular leucomalacia (Review: Ref. [339]).

## 5. Energy metabolism and calcium homeostasis

The normal functioning of the brain is not only dependent on an adequate oxygen supply but also requires sufficient glucose. Transmission of electric impulses and biosynthetic reactions within the neurones require a continuous source of energy which is produced by the breakdown of glucose. The most important metabolic pathway for glucose is aerobic glycolysis by which glucose is metabolised to pyruvate. Pyruvate is then metabolised further through the energy-producing citric acid cycle. The electrons thereby released yield energy as they pass down the respiratory chain in the mitochondria. The energy released on each transfer of electrons is incorporated into molecules of ATP, synthesized from the precursor ADP and high energy phosphate (Pi). ATP is the basic source of energy for all energy requiring reactions in the brain [337].




Fig. 4. Primary and secondary effects of the increased intracellular calcium concentration during and after cerebral ischemia [305]. XDH, xanthine dehydrogenase; XO, xanthine oxidase; PAF, platelet aggregating factor; FFAs, free fatty acids; DAG, diacylglyceride; LPL, lysophospholipids.

Whereas, during moderate hypoxemia, the fetus is able to maintain cerebral metabolism and adequate levels of ATP by speeding up the rate of anaerobic glycolysis [29,30,35], an acute reduction of the fetal oxygen supply will lead to a breakdown of energy metabolism in the cerebral cortex within a few minutes (Table 3) [27,28]. The ionic gradients for  $\text{Na}^+$ ,  $\text{K}^+$  and  $\text{Ca}^{2+}$  across the cell membranes can no longer be regulated since the  $\text{Na}^+/\text{K}^+$ -pump stops working through lack of energy. The membrane potential approaches 0 mV [133]. The energy depleted cell takes up  $\text{Na}^+$ , and the subsequent fall in membrane potential induces an influx of  $\text{Cl}^-$  ions. This intracellular accumulation of  $\text{Na}^+$  and  $\text{Cl}^-$  ions leads to swelling of the cells as water flows in through osmosis. Cell oedema is therefore an inevitable consequence of cellular energy deficiency [305].

In addition, loss of membrane potential leads to a massive influx of calcium down the extreme extra-/intracellular concentration gradient. It is currently thought that the excessive increase in intracellular calcium levels, the so-called calcium-overload, leads to cell damage by activating proteases, lipases and endonucleases [305]. Some of the cellular mechanisms that are activated by the calcium influx occurring during ischemia are shown in Fig. 4: alteration of the arachidonic acid cycle affecting prostaglandin synthesis, disturbances of gene expression and protein synthesis and increased production of free radicals and obstruction of the axonal transport system through disaggregation of microtubuli.

## 6. Excitatory neurotransmitters

As early as 1969, Olney succeeded in demonstrating that neuronal cell death could be induced by the exogenous application of glutamate, an excitatory neurotransmitter [252]. In subsequent years, this observation was confirmed in both immature and adult animals of various species including primates [253]. In 1984, Rothman showed that glutamate antagonists could prevent anoxic cell death in hippocampal tissue cultures [285]. That same year, Benveniste et al. reported an excessive release of glutamate into the extracellular space during cerebral ischemia in vivo [24], from which they concluded that glutamate might play an important role in neuronal cell death following ischemia [256,285–287].

Glutamate activates postsynaptic receptors, consisting of five subunits, that form ionic channels permeable to cations (Fig. 5) [294]. Three classes of ionotropic glutamate receptors have been identified on the basis of their pharmacological response to specific agonists such as amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), kainate (KA) and *N*-methyl-D-aspartate (NMDA). These are referred to as the AMPA-, KA- and NMDA-receptors [230]. The corresponding channels are permeable




Fig. 5. Regulation of glutamate-mediated synaptic transmission. After depolarization of the presynaptic neuron vesicular glutamate is released by exocytosis into the synaptic cleft. Released glutamate activates postsynaptic ionotropic (NMDA, AMPA, Kainate) receptors and pre- or postsynaptic metabotropic (G-protein coupled) receptors. Glutamate action is terminated by  $\text{Na}^+$ -dependent uptake in the presynaptic neuron as well as in glial cells [248].

to  $\text{Na}^+$  and  $\text{K}^+$  ions, while those of the NMDA-receptor also exhibit  $\text{Ca}^{2+}$ -permeability. Glutamate also activates the metabotropic receptors that regulate intracellular G-protein signal cascades [239]. The best characterised receptor in this family is the quisqualate receptor that mediates the hydrolysis of phosphatidylinositol-4,5 biphosphonate ( $\text{PIP}_2$ ) into the messenger molecules 1,4,5-triphosphate ( $\text{IP}_3$ ) and diacyl-glycerol. The activation of each of these receptors leads to an increase in the levels of free calcium in the cell cytoplasm. The NMDA-receptor regulates a calcium channel, the metabotropic receptors induce an emptying of intracellular calcium stores while the AMPA/KA receptors open a voltage-dependent calcium channel by membrane depolarisation. The increase in free calcium within the cell activates proteases, lipases and endonucleases that then initiate processes leading to cell death [62,303,304].

There is no longer any doubt that glutamate release plays a critical role in neuronal cell death after focal cerebral ischemia such as that caused by an arterial embolus [217]. Glutamate antagonists have been shown to exert a strong neuroprotective effect against hypoxic–ischemic brain damage in adult [174,263,336] and even in neonatal animals [10,93,101,138,212,246,254]. In neonatal rats, it was shown that glutamate release during and after an hypoxic–ischemic insult could evoke epileptogenic activity and that this effect was dependent on the maturity of the brain. In rats, the most marked effect was observed 10 to 12 days after birth (Fig. 6) [159]. The reason for this seems to be a developmental change in the subunits of the glutamate receptor which increases the neurone's permeability to calcium [160,161]. Furthermore, the levels of GABA, one of the most important inhibitory neurotrans-




Fig. 6. EEG-recording during acute hypoxia (3% O<sub>2</sub>) in rats of different post-gestational ages. Epileptogenic activity is registered in 10–12-day-old rats (P10–12) during hypoxia, whereas in the older animals (P50–60) isoelectric EEG-activity is registered [159,161].

mitters in neuronal tissue, are very low at this stage of development [70,255,313].

As shown in adult animals, epileptogenic impulses in the vicinity of a brain infarct cause a considerable rise in metabolic activity. In an inadequately perfused section of brain tissue such as the penumbra surrounding an infarct, this can rapidly lead to an imbalance between cell metabolism and blood circulation, resulting in brain damage [148]. In addition, the formation of LTPs (long-term potentials), that play an important role in synaptic plasticity and hence, in learning processes, may be disturbed by the induced epileptogenic activity [42]. Long-term neurological damage is the inevitable consequence in the children affected.

In global ischemia, such as that caused by cardiac insufficiency, the situation is quite different to that in focal ischemia. As shown in adult animals, it is far less clear whether glutamate is directly involved in neuronal cell death [2,4,50,183,187,326,344]. As Hossmann points out in his 1994 review article, a number of observations argue




Fig. 7. Protein synthesis rate in hippocampal slices from mature fetal guinea pigs 12 h after in vitro ischemia. The ischemic period lasted between 20 and 40 min (I 20, I 30, I 40). Protein synthesis rate was not affected neither by application of glutamate nor by glutamate antagonists (MK-801 [100 μM], kynurenic acid [500 μM]). Values are given as mean ± S.D. Statistical analysis was performed by ANOVA followed by Scheffé's *F*-test (\**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 [ischemia vs. control]) [36].

against any major involvement of glutamate in processes leading to neuronal cell death after global ischemia [148]. (1) Neither the pattern of glutamate release during ischemia nor the cerebral distribution of glutamate receptors matches the regional manifestation of brain damage after global ischemia [68,105,208,225]. (2) Glutamate toxicity in cell cultures from vulnerable brain areas was found to be no higher than in cultures from non-vulnerable regions [87,148]. (3) In contrast to the effects of *in vitro* ischemia, application of glutamate to cell cultures or hippocampal tissue slices caused no prolonged inhibition of protein synthesis [58,84,87].

Since then, the possibility of glutamate playing a key role in the induction of brain damage either during or directly after global ischemia, even in the immature brain, has been effectively excluded by the following observations: Application of glutamate or glutamate antagonists to hippocampal slices from guinea pig fetuses did not affect post-ischemic protein biosynthesis, a parameter used as an early marker of neuronal cell death (Fig. 7) [36]. Furthermore, the glutamate antagonist lubeluzole was found to have no neuroprotective effect in a model of cerebral ischemia in mature sheep fetuses (Fig. 3, Ref. [98]). However, it is possible that later, during the reperfusion phase after cerebral ischemia, glutamate-induced epileptogenic activity does cause brain damage. This possibility will be discussed further on.

## 7. Protein biosynthesis

As animal experiments show, inhibition of protein synthesis plays a key role in the post-ischemic processes leading to neuronal cell damage [146]. Protein synthesis is reduced both during ischemia and in the early post-ischemic phase in vulnerable and non-vulnerable brain areas [171]. At the end of the ischemic period, protein synthesis in non-vulnerable regions recovers to pre-ischemic levels, while in vulnerable regions it remains inhibited [45, 324,347]. Thus, the inhibition of protein synthesis appears to be an early indicator of subsequent neuronal cell death [146]. This observation ties in with the results of experiments demonstrating the neuroprotective effect of hypothermia or barbiturates after cerebral ischemia [348,352]. Shortly after cerebral ischemia, the usual inhibition of protein synthesis set in, however, the recovery phase in the normally vulnerable areas was now much shorter (Fig. 8), and was accompanied by far less pronounced neuronal cell damage. Similar findings were reported in connection with developmental variations in the response of the brain to ischemic insults: Protein synthesis in the fetal brain was found to recover much faster from ischemic insults than that in adult brains [31]. The prolonged inhibition of protein synthesis is, therefore, an early indicator and possibly also one of the causes of neuronal cell damage arising after ischemia [146].




Fig. 8. Autoradiographic evaluation of protein synthesis before (control) and at two recirculation times (2 h and 2 days) after 5 min bilateral carotid artery occlusion in gerbil. Left: untreated animals. Right: treated animals (50 mg/kg pentobarbital *i.p.*, shortly after ischemia). Note similar reduction of protein synthesis after 2 h of recirculation but recovery in all regions including CA1 sector in the barbiturate-treated animals after 2 days recovery (arrows) [146].

Electron microscopic and biochemical studies have shown that post-ischemic inhibition of protein synthesis is accompanied by a disaggregation of the polyribosomes [135,170,171]. This disaggregation seems to occur not during but after ischemia, and involves a dissociation of the monoribosomes into their smaller and larger subunits [171]. Ribosomes disaggregate when starting a new polypeptide chain takes longer than chain extension or termination. The disaggregation of the polyribosomes cannot occur during ischemia, because the breakdown of energy metabolism hinders all stages of protein synthesis (initiation, elongation and termination) [145]. However, after ischemia, the regenerated energy metabolism reactivates only the chain elongation and termination stages of protein synthesis, and not initiation. This leads, inevitably to a disaggregation of the polyribosomes and a sustained inhibition of protein biosynthesis [146]. Recent research suggests that the post-ischemic inhibition of protein synthesis is based on a disturbance of calcium homeostasis in the endoplasmic reticulum [265,266].

Finally, post-ischemic protein synthesis seems to be involved in the cellular suicide program known as apoptosis. This view is supported by studies showing that apoptotic cell death could be prevented by application of the protein synthesis inhibitor, cycloheximide [109].






## 8. Secondary cell damage during reperfusion

In cerebral tissue capable of regeneration after an ischemic insult, energy metabolism can be seen to recover rapidly [31,146]. A few hours later, however, the energy status is diminished once again in the affected tissue [43,269]. Simultaneously, a secondary cell oedema develops, followed a little later by epileptogenic activity that can be monitored on EEG. These events are quite probably brought about or modulated by oxygen radicals, nitric oxide (NO), inflammatory reactions and excitatory amino acids, particularly glutamate.

### 8.1. Oxygen radicals

During cerebral ischemia, the cut back in oxidative phosphorylation rapidly diminishes reserves of high-energy phosphates. Within a few minutes, considerable amounts of adenosine and hypoxanthine accumulate. During reperfusion these metabolic products are metabolised further by xanthine oxidase to produce xanthine and uric acid [211]. The activity of xanthine oxidase in the resting brain is very low [3], but during cerebral ischemia a massive conversion of xanthine dehydrogenase to xanthine oxidase takes place, regulated by the calcium-dependent protease calpain [169,211]. The breakdown of hypoxanthine by xanthine oxidase in the presence of oxygen, produces a flood of superoxide radicals. These are then

converted by superoxide dismutase to hydrogen peroxide [94,95]. By the Haber–Weiss reaction shown below, hydrogen peroxide and tissue iron can then combine to form hydroxyl radicals.



The so-called oxygen radicals then cause various forms of tissue damage [76,77,127,218,322,342]. Similarly, the increased rate of arachidonic acid metabolism in brain tissue or activated leucocytes after ischemia can also produce large amounts of oxygen radicals (Review: Ref. [139]).



Numerous studies have shown that oxygen radicals play an important role in processes leading to neuronal cell damage (Ref. [329], Review: Ref. [128]). In adult animals, various degrees of neuroprotection against ischemic insults can be achieved through the inhibition of xanthine oxidase by application of oxygen radical scavengers and iron chelators [18,40,56,125,172,191,209,223,267]. Oxygen radicals also appear to be involved in mechanisms underlying neuronal cell death in immature animals. The rate of lipid peroxidation was found to be considerably increased after hypoxia in fetal guinea pigs and newborn lambs [1,108,224]. The longer the gestational age, the greater this increase was [224]. Furthermore, marked production of oxygen radicals was observed after hypoxia both in vitro, in cultures of fetal neurones, and in vivo, in neonatal mice [136,250]. There is also evidence that the infarct volume can be reduced in a model of focal ischemia in neonatal rats by application of allopurinol, an inhibitor of xanthine oxidase and oxygen radical scavengers [256].

### 8.2. NO

NO is a free radical synthesized by NO-synthase in endothelial cells and neurones in response to rises in levels of intracellular calcium. Beside this endothelial and neuronal form of NO-synthase, another form of the enzyme is found in neutrophil granulocytes and microglia. This isoform can be stimulated by cytokines released by activated macrophages. It is calcium-independent and can sustain NO production for several days [236]. Beckman et al., however, demonstrated that NO and superoxide radicals combine to produce peroxynitrite that spontaneously decomposes to form hydroxyl radicals, nitrogen dioxide and  $\text{NO}_2^+$  [19,20]. Thus NO, like free iron, can raise the

toxicity of superoxide radicals significantly by converting them to highly potent radicals that cause considerable cell damage [154].

During cerebral ischemia, a massive influx of intracellular calcium takes place through various channels, regulated, among other things, by the neurotransmitter glutamate [63,304]. The rise in intracellular calcium activates NO-synthase [88,99], which produces NO, citrulline and water from arginine, NADPH and oxygen.



There is also an accumulation of cGMP [21]. Since there is no oxygen available during ischemia, NO cannot be synthesized until the reperfusion phase [21]. Likewise, large numbers of superoxide radicals are produced by xanthine oxidase and via other pathways in the mitochondria during and, to an even greater extent, after ischemia [199]. During reperfusion, NO and superoxide radicals combine, as described above, to produce peroxynitrite, leading to the formation of more potent radicals. Destruction of the tissue is the inevitable result [21]. Investigations of the action of inhibitors of NO-synthase in models of cerebral ischemia in adult animals have yielded highly variable results [49,55,74,78,130,177,234,240,245,272,297,357,358]. This can be explained by the fact that the neuroprotective effect of NO-synthase blockers after ischemia, that is brought about by a lowering of NO production and consequent reduction of the build-up of potent radicals, is counteracted by a marked vasoconstriction induced by the fall in NO concentration in endothelial cells [75]. Thus, Huang et al. found markedly smaller infarct loci after occlusion of the A. cerebri media in mice whose expression of the neuronal form of NO-synthase had been blocked than in the wild type of the animal [151]. The same group was also able to protect the brain from ischemic insults by application of selective blockers of neuronal NO-synthase [75].

To date, hardly any studies have investigated the importance of NO in neuronal cell death in neonates or fetuses. After a hypoxic–ischemic insult in neonatal rats, a greater number of neurones were found to contain NO-synthase [141]. The activity of this NO-synthase, however, appeared to be diminished [162]. Furthermore, two peaks of NO production were detected in this animal model: one during hypoxia and the other during the reoxygenation period. The neuronal and the inducible form of NO-synthase seems to be differently involved in this process [142]. Some authors succeeded in preventing ischemic lesions in the brains of immature animals through application of NO-blockers [13,129,330], while other research teams were unable to achieve this effect or observed, instead, a worsening of the damage [205,309]. As already mentioned, this discrepancy may have arisen from the different effects of

NO-blockers on vascular endotheli and neurones. In our investigations of the effect of blocking NO-synthase we therefore by-passed the cardiovascular system, by carrying out experiments on hippocampal slices [38]. Although post-ischemic NO-production could be completely blocked with NO-inhibitors, this intervention had no influence on the post-ischemic inhibition of protein biosynthesis, a parameter used as an early indicator of neuronal cell death




Fig. 9. (Top panel) cGMP concentrations in hippocampal slices from mature fetal guinea pigs after different durations of in vitro ischemia (10–40 min). A portion of the tissue slices was incubated for 30 min, before, during and 10 min after ischemia, in 100 μM *N*-nitro-*L*-arginine (NNLA). After 10 min recovery from 10 to 40 min of ischemia, a marked rise in cGMP levels was observed in tissue slices that had not been incubated in NNLA. Note that application of NNLA blocked the ischemia-induced elevation of cGMP almost completely. (Bottom panel) Protein synthesis rate in hippocampal slices from mature fetal guinea pigs after different durations of in vitro ischemia (20–40 min) and a recovery period of 12 h. A portion of the tissue slices was incubated in 100 μM NNLA for 30 min before, during and 12 h after ischemia. Protein synthesis rate was reduced to 50% of initial levels after 40 min ischemia. Note that blocking of NO-synthase with NNLA did not improve the post-ischemic recovery of protein synthesis. The statistical significance of differences between groups was assessed by ANOVA and the Scheffé post-hoc test (Top panel:  $P < 0.05$  (ischemia vs. control), Bottom panel:  $P < 0.05$  (NNLA vs. without NNLA)) [38].

(Fig. 9). Whether or not NO is directly involved in the pathogenesis of neuronal cell death following ischemia in fetuses therefore remains an open question.

### 8.3. Inflammatory reactions

As various studies have shown, ischemia and subsequent reperfusion can set off an inflammatory reaction in the brain (Fig. 10) [91,288]. Expression of a wide variety of cytokines, e.g., IL-1, IL-6, transforming growth factor- $\beta$ , and fibroblast growth factor, was observed. In rats, mRNA of IL-1 was expressed within 15 min of global cerebral ischemia [222]. Cytokines appear to be formed in activated microglia [100,215,232]. They are thought to mediate the migration of inflammatory cells within the reperfused tissue.

Through increased expression of the adhesion molecules P- and E-selectin and ICAM-1 on the endothelial cells and of integrins on leukocytes, granulocytes become attached to the endothelium, migrate through the vessel wall and accumulate in the interstitium [90,110,132,210,251,259,340]. There, after further activation by cytokines, they synthesize oxygen radicals, especially superoxide radicals that proceed to damage neuronal tissue. The role of inflam-

matory cells in the pathogenesis of secondary cell damage was further elucidated in reperfusion experiments using blood lacking granulocytes, or antibodies to adhesion molecules and trials on transgenic mice [126,140,152,200,278,338,355]. Especially in the brain of immature fetuses exposed to a severe intrauterine infection such pathophysiological mechanisms appear to play a critical role [113,354].

### 8.4. Glutamate

Williams et al. observed epileptiform activity in mature sheep fetuses about 8 h after 30 min of global cerebral ischemia that reached a peak 10 h after the ischemic period [350]. They were able to completely inhibit this epileptiform activity by application of the glutamate antagonist MK-801, and show that the resulting brain damage was markedly reduced in the treated animals (Fig. 11) [320]. This suggests that a secondary wave of glutamate release or an imbalance between excitatory and inhibitory neurotransmitters during reperfusion may induce epileptiform bursts of neuronal activity that can lead to an uncoupling of cell metabolism and blood flow. This would automatically impair pathways of energy metabolism and cause a secondary wave of cell damage [148].




Fig. 10. Mechanisms of recirculatory induced brain damage. Ischemia and recirculation are possible inducers of gene expression and formation of oxygen radicals. Endothelium-derived oxygen radicals induce expression of adhesion molecules to allow granulocytes crossing the blood-brain barrier. The formation of oxygen radicals, glutamate-induced excitotoxicity, and cytokines produced by activated microglia are damaging neuronal cells. NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; TGF, transforming growth factor; PAF, platelet-aggregating factor; ICAM-1, intercellular adhesion molecule 1; IL, interleukin;  $\text{ONOO}^\cdot$ , Peroxynitrite [91].

## 9. Apoptosis and post-ischemic genome expression

It is still unclear whether secondary cell death after ischemia is necrotic or apoptotic. The latter condition is characterised by a shrinking of the cell, blebbing of the cell

membrane, condensation of chromatin and DNA fragmentation induced by a calcium-dependent endonuclease (Fig. 12) [327]. In DNA electrophoresis, this fragmentation can be recognised by a typical DNA ladder [178,192,214,327]. In neuronal cell cultures, apoptosis can be prevented by




Fig. 11. (a) Registration of electrocortikogramm (ECOG), nuchal electromyogramm (nuchal EMG) and arterial blood pressure (BP) in term fetal sheep 9 h after 30 min of global cerebral ischemia. Note the absence of epileptogenic activity in treated (B; 0.3 mg/kg MK-801 over 36 h starting 6 h after ischemia) in contrast to untreated fetuses (A, B). (b) Neuronal cell damage 72 h after global cerebral ischemia of 30-min duration in term fetal sheep. Treated (0.3 mg/kg MK-801 over 36 h starting 6 h after ischemia) vs. untreated fetuses. \* $P < 0.05$ ; PSCX, parasagittal cortex; LTCX, lateral cortex; STR, striatum; DG, dentate gyrus; CA1, 2, 3, 4 hippocampal sectors; THAL, thalamus; AMG, amygdala [320].




Fig. 12. Apoptosis in neuronal cell culture. (a) Illustration of an intact neuron (arrowhead) and an apoptotic neuron with typical intracytoplasmic vesicles (arrow). (b) Fluorescence staining of 10-day-old apoptotic neurons which shows fragmentation of nuclei and condensation of chromatin (arrows). (c) DNA-fragmentation in neurons illustrated by the TUNEL-method [52].

post-ischemic inhibition of protein synthesis using cycloheximide, or inhibition of RNA synthesis with actinomycin or through inhibition of endonuclease with aurin tricarboxylic acid. In addition, the amount of apoptotic cell death can also be reduced by inhibition of caspases in neonatal rats after a hypoxic–ischemic insult [61]. These findings all point towards the existence of a built-in cellular suicide programme [274,281]. It is also possible that the form of secondary cell death following ischemia is determined by the severity of the primary insult. Thus, Dra-

gunow et al. were able to demonstrate that delayed cell death in immature rat brains subjected to a 15-min period of hypoxic–ischemia was of an apoptotic nature, while after a 60-min insult, the neuronal damage was predominantly necrotic [85]. Other investigators have also reported correlations between the severity of the insult and the extent of apoptotic cell death [190,216].

As has since been shown in numerous studies, including some on immature animals, cerebral ischemia can induce the expression of a whole series of proto-oncogenes [44,82,92,137,173,233,308]. Proto-oncogenes themselves code for proteins that act as transcription factors and regulate the expression of genes modulating cell growth and differentiation. They are also termed ‘immediate early genes’ since they are expressed within a few minutes of an insult.

These include c-fos, c-jun, jun-B, jun-D. The transcriptional activity of proteins of the fos-family is caused by a heterodimer formation with proteins of the jun-family [194]. Fos- and jun-proteins can also form dimers with proteins of the ATF- and CREB families and thereby increase their promoter affinity [122].

As already mentioned, transcription factors control the expression of genes participating in cell growth and differentiation. Depending on the severity of the insult, these factors are therefore capable of initiating processes leading to apoptotic cell death or triggering a recovery programme. Recent research findings have indicated that the proto-oncogenes and cell cycle-dependent proteins such as cyclin D1 [325,349], and tumor suppressor genes such as p53 are critically involved in this control function (Fig. 13). Thus, the expression of the p53 gene was demonstrated in focal cerebral ischemia or kainate-induced seizures causing neuronal DNA lesions in the rat [189,290]. Weaker expression of p53 in transgenic mice subjected to cerebral ischemia was accompanied by a milder degree of brain damage [73]. As we know from other organ systems, p53 protein recognizes and binds DNA-lesions, possibly straight onto its C-terminal [155,186]. Furthermore, it acts as a transcription factor, inducing the expression of p21 [89], that inhibits cyclin-dependent kinases [134]. p21, on the other hand, restricts the ability of PCNA (proliferating cell nuclear antigen) to activate DNA polymerase  $\delta$  the principle replicative DNA polymerase [341]. In apparent contradiction with its role in suppressing cell proliferation via p21 expression, p53 also increases the mRNA and protein for cyclin D1. Cyclin D1 is a major effector of G1 phase entry supporting the contention that besides its role in the cell cycle, it may also be involved in p53-mediated apoptosis.

If lesion-induced signal transformation pathways or the ectopic expression of growth factors, some of which are potent mitogens, induce the expression of cell cycle components in postmitotic neurons, the concomitant DNA damage-induced p53 may halt or antagonize this pathway leading to a possible conflict in decisions. p53-mediated halt in replication may be associated with a p53-dependent




Fig. 13. Diagram illustrating the central role of p53 in mediating DNA repair or apoptosis in neurons during and after cerebral ischemia [168]. Gadd45, growth-arrest-and-DNA-damage-inducible; cdk4, cyclin D-dependent kinase; for further abbreviations see text.

transactivation of the ubiquitously expressed mammalian gene Gadd45 (growth-arrest-and-DNA-damage-inducible) [167]. Its product is involved in DNA repair and interacts with PCNA. PCNA is implicated in replication of cellular DNA, but is also required for DNA excision repair [300,307]. Besides p53, PCNA, Gadd45, and p21 are also induced in brain pathologies suggesting that some of the molecular mechanisms referred to in non-neural cells, may also hold true in the brain. Depending upon the developmental stage of the injured brain and the extent of cell damage on the one hand, and upon damage-induced p53 expression on the other, neurons may attempt cell cycle entry, a process that will involve a certain amount of DNA repair, or may only attempt transcription-coupled DNA repair. The cell death decision may result from the impossibility to proceed with both processes. Indeed, it has recently been shown in vitro that the p53 transcription factor, besides its role in halting replication while favoring repair, attenuates *Bcl-2* expression, and is a direct transcriptional activator of the *Bax* gene, whose product is shown to induce apoptosis [9,168,227–229,275].

## 10. Therapeutic strategies

Despite the critical clinical and socio-economic consequences of perinatal brain damage, no effective therapeutic strategies have yet been developed to prevent its causes.

However, as already mentioned, some promising possibilities have been revealed through animal experiments that could be developed and tested in clinical studies. Since a significant proportion of neuronal cell damage is brought about by pathophysiological processes that first begin several hours or even days after an ischemic insult (see Sections 8 and 9), the setting up of a therapeutic window would be feasible. In the following passages, current therapeutic concepts will be described by which neuroprotection has been achieved in animal models.

### 10.1. Hypothermia

The induction of mild hypothermia has raised interesting possibilities for neuroprotection from cerebral ischemia (Review: Ref. [203]). Various publications dating back to the 1950s, have described the therapeutic benefits of hypothermia in brains subjected to a wide variety of insults including brain trauma [264,295], cerebral haemorrhage [150], cardiac arrest [26], carbon monoxide poisoning [71], neonatal asphyxia [346] and seizures [48]. Based on these findings, routine induction of hypothermia was introduced early on in heart and brain surgery to protect the brain in the event of iatrogenic intraoperative cardiac arrest [47,86,188,197,237]. Over the last few years, induction of mild hypothermia has been examined once again as a means of protecting the brain from ischemically induced damage. Experimental studies on adult animals have shown

Table 4

Protein synthesis rate as percentage of control in hippocampal slices from mature fetal guinea pigs 12 h after in vitro ischemia. Hypothermia was induced by lowering the incubation temperature from 37° to 33° [37]. Values are given as mean  $\pm$  S.D.

|                 | Percentage control           |                                |
|-----------------|------------------------------|--------------------------------|
|                 | Normothermia                 | Hypothermia                    |
| Control         | 100.0 $\pm$ 16.5             | 100.0 $\pm$ 12.1               |
| Ischemia 10 min | 91.7 $\pm$ 12.6              | 114.8 $\pm$ 11.5 <sup>b</sup>  |
| Ischemia 20 min | 67.8 $\pm$ 8.7 <sup>a</sup>  | 95.1 $\pm$ 9.2 <sup>b</sup>    |
| Ischemia 30 min | 61.5 $\pm$ 15.9 <sup>a</sup> | 85.8 $\pm$ 3.1 <sup>b</sup>    |
| Ischemia 40 min | 50.8 $\pm$ 14.1 <sup>a</sup> | 78.2 $\pm$ 19.2 <sup>a,b</sup> |

<sup>a</sup> $P < 0.05$  (ischemia vs. control).

<sup>b</sup> $P < 0.05$  (normothermia vs. hypothermia).

that lowering of the brain temperature by 3–4°C during global cerebral ischemia reduces neuronal cell damage dramatically [53,67,111,345,348]. Furthermore, the treated animals were found to perform better than controls in subsequent learning and behavioural tests [111].

The author's research team was also able to demonstrate a neuroprotective effect of mild hypothermia in fetal brain tissue subjected to ischemic insults. They found that the post-ischemic recovery of protein synthesis and energy metabolism in hippocampal slices from mature guinea pig fetuses was considerably improved, in comparison to controls, by induction of mild hypothermia (Table 4) [32,37].

In a recently published study, Gunn et al. described the effects of moderate hypothermia in sheep fetuses subjected to severe global cerebral ischemia in utero [117]. Hypothermia was initiated during the reperfusion phase, 90 min after induction of 30 min of ischemia, in a four-vessel occlusion model, and maintained for 72 h. By this method, it was possible to reduce the extent of neuronal cell damage in areas of the cortex cerebri by up to 60% (Fig. 14) [117]. Even if hypothermia was started 5.5 h after ischemia, neuroprotection could be observed in this animal model [119]. Based on these results, many authors now consider the induction of hypothermia during and particularly after a hypoxic–ischemic insult to be an effective therapeutic strategy [54,117]. In fact, Gunn et al. demonstrated in a recent clinical study that selective head cooling in newborn infants after perinatal asphyxia is a safe and convenient method of quickly reducing brain temperature [118].

The mechanisms underlying the neuroprotective effect of mild hypothermia are still unclear (Review: Ref. [203]). For a long time, it was assumed that hypothermia exerted its effect by reducing cerebral oxygen consumption [23,41] and a delayed emptying of energy stores during ischemia [175,219,220,311,312]. However, this hypothesis could not be confirmed in experiments on hippocampal slices. The fall in ATP levels during ischemia did not correlate with the post-ischemic inhibition of protein synthesis, a param-




Fig. 14. (a,b) Section of the parasagittal cortex in (370-fold magnification) in term fetal sheep 5 days after 30 min of cerebral ischemia followed by normothermia (a) or mild hypothermia (b). (a) Complete neuronal necrosis (normothermic group). (b) Minor degree of neuronal cell damage (hypothermic group) [117].

ter taken as a measure of neuronal cell damage [37]. Whether the effect of mild hypothermia can be explained by an improved recovery of energy metabolism directly after ischemia is also debatable. Chopp et al. found only a minimal improvement in concentrations of creatine phosphate and ATP after induction of mild hypothermia in rats subjected to global cerebral ischemia [64]. Nor, as *in vitro* experiments have demonstrated, can modulation of cerebral flow after ischemia be the sole basis of the neuroprotective effect of hypothermia [37]. Although the release of excitatory amino acids both during and after ischemia is prevented by mild hypothermia [54,106], it remains unclear whether these findings are simply an epiphenomenon or the true basis of hypothermia's neuroprotective effect [37]. Other effects that appear to be associated with the therapeutic induction of mild hypothermia after cerebral ischemia are: reduced oxygen radical formation [60,104], a stabilisation of the blood-brain barrier [83] and a modification of enzyme activation [57,66,353], etc.

### 10.2. Pharmacological intervention

Now that the pathophysiological mechanisms underlying neuronal cell damage are better understood, diverse possibilities present themselves for pharmacological intervention. Interest is currently focused on the administration of oxygen radical scavengers, NO inhibitors, glutamate antagonists, calcium antagonists, growth factors and anti-cytokines. Table 5 presents all the potential neuroprotective substances currently under investigation (modified according to Ref. [335]).

### 10.3. Magnesium

The last interesting therapeutic approach to be discussed emerged from a retrospective analysis carried out by Nelson and Grether. Recently, in a population of 155,636 infants, these authors showed that ante-partum application of magnesium considerably lowered the incidence of cerebral palsy in newborns weighing less than 1500 g [238]. The incidence of moderate to severe cerebral palsy was 4.8% in this group. Seventy-five matched pairs were compared with the 42 children suffering from cerebral palsy. In the control group, 36% of the children had been treated with magnesium, whereas, in the group with cerebral palsy only 7% had been treated. This difference was statistically highly significant (Fig. 15). The same effect could be observed in the children of patients not suffering from pre-eclampsia. The protective effect of magnesium was independent of variables such as the administration of tocolytic agents or drugs to accelerate fetal lung development or any other maternal or fetal risk factors. Almost identical results were recently obtained in a retrospective study carried out by Schendel et al. [292].

As numerous animal experiments, both *in vivo* and *in vitro* have shown, magnesium can reduce the extent of

ischemically induced neuronal cell damage [165,166, 213,284,332]. This neuroprotective effect could be based on a number of pathophysiological mechanisms, one being the well-known vasodilatory properties of magnesium as a calcium antagonist [6,273,296,317]. It has also been established that hypoxic–ischemic brain damage is partly caused by the intracerebral release of excitatory amino acids [286]. Magnesium may protect neurones from anoxic damage by preventing the presynaptic release of these substances [166,284]. The massive intracellular influx of calcium that takes place during ischemia plays a key role in the development of neuronal cell damage [62,304]. Magnesium blocks the glutamate-controlled NMDA receptor [201,244] as well as voltage-dependent calcium channels, hindering the influx of extracellular calcium into the neurons. The activation of numerous calcium-dependent proteases, lipases and endonucleases is thereby counteracted. As already mentioned, the release of excitatory amino acids during and after cerebral ischemia in damaged brain regions can lead to epileptiform activity. This, in turn, can create an imbalance between blood flow and cell metabolism, causing brain damage [148]. Magnesium has proven anti-convulsive properties [292], that can diminish epileptiform activity and thus reduce the extent of possible brain damage. The lowering of the rate of cell metabolism has been put forward as another possible explanation of the neuroprotective effect of magnesium [166,314].

In the United States, magnesium has been administered for over 20 years for treatment of premature contractions and pre-eclampsia [69,301]. Magnesium crosses the placental barrier and enters the fetal blood plasma [72,112]. The concentration in the fetal blood plasma corresponds roughly to that in the maternal plasma [72,112]. Very high magnesium levels can lead to a temporary lowering of muscle tone, weakened reflexes and respiratory depression in the newborn. Serious complications in either the infant or mother are, however, extremely rare [193]. The Collaborative Eclampsia Trial showed that infants of mothers treated with magnesium for EPH gestosis are less frequently intubated or transferred to the children's hospital for intensive care than those whose mothers received phenytoin [323]. However, a recently published study described for the first time an increased child mortality after pregnancies in which expectant mothers were treated with *i.v.* magnesium [226]. However, a large percentage of these infants died after the neonatal period. Some of the deaths were caused by feto-fetal transfusion syndrome in twins or congenital abnormalities, making any causative link between the magnesium therapy given during pregnancy and these fatalities quite unlikely. This has been confirmed by a new retrospective analysis carried out by Grether et al. [114].

To date, research findings strongly suggest that administration of magnesium can lower the incidence of cerebral palsy in immature neonates weighing less than 1500 g. However, the consistency of this therapeutic effect still

Table 5

Pharmacological intervention on hypoxic/ischemic brain damage in various models of hypoxia/ischemia [335]

UCO: unilateral occlusion of carotid arteries, BCO: bilateral occlusion of carotid arteries, VOA: occlusion of the vertebro-occipital anastomoses, BP: arterial blood pressure, bFGF: basic fibroblast growth factor.

| Treatment class                                | Treatment details                                                                                                                                                                                                                                                                                                                                                                                                                                        | Age/species                                                                                                                                                                                                                                                                 | Hypoxic/ischemic insult                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Time of treatment with respect to insult                                                                                                                                        | Neuroprotection/pathology                                                                                                                                                                                | Refs.                                                                                                                                                      |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VSCC's antagonists                             | Flunarizine (30 mg/kg)<br>Flunarizine (30 mg/kg)<br>Flunarizine (30 mg/kg)<br>Flunarizine (9 mg/kg)<br>Flunarizine (1 mg/kg)<br>Nimodipine (70 µg/kg or 0.5 mg/kg)<br>Nimodipine (0.5 mg/kg)<br>MK-801 (10 mg/kg)<br>MK-801 (10 mg/kg)<br>MK-801 (1 mg/kg)<br>MK-801 (0.3 mg/kg)<br>MK-801 (0.3 bw. 0.5 mg/kg)<br>MK-801 (0.75 mg/kg)<br>MK-801 (3 mg/kg)<br>MK-801 (0.3 mg/kg)<br>Felbamate (300 mg/kg)<br>NBQX (20 + 20 mg/kg)<br>BW1003C87 (10 mg/kg) | 7 days/rat<br>7 days/rat<br>21 days/rat<br>fetal sheep<br>fetal sheep<br>7 days/rat<br>0–3 days/pig<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>0–3 days/pig<br>Schaffet<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat | UCO + 2 h 8% O <sub>2</sub><br>UCO + 3 h 8% O <sub>2</sub><br>UCO + 2 h 8% O <sub>2</sub><br>30 min BCO (+ VOA)<br>30 min BCO (+ VOA)<br>UCO + 3 h 8% O <sub>2</sub><br>30 min BCO + hypotonia and 15 min 6% O <sub>2</sub><br>BCO + 1 h 8% O <sub>2</sub><br>BCO + 1 h 8% O <sub>2</sub><br>UCO + 3 h 8% O <sub>2</sub><br>UCO + 2 h 8% O <sub>2</sub><br>UCO + 1.5 h 7.6% O <sub>2</sub><br>UCO + 1.5 h 7.6% O <sub>2</sub><br>30 min BCO + hypotonia and 15 min 6% O <sub>2</sub><br>30 min global ischemia<br>BCO + 1 h 6.5% O <sub>2</sub><br>UCO + 1.5 h 7.6% O <sub>2</sub><br>UCO + 1.5 h 7.7% O <sub>2</sub> | pre<br>pre<br>pre<br>pre<br>pre<br>post<br>post<br>post<br>pre, intra<br>pre, intra<br>post (0 h)<br>post (0 h)<br>post (0 h)<br>post (6–36 h)<br>post<br>post (0 + 1 h)<br>pre | partial<br>partial<br>partial<br>partial<br>partial<br>no effect<br>no effect<br>total<br>partial<br>partial<br>partial<br>partial<br>no effect<br>no effect<br>partial<br>partial<br>partial<br>partial | [306]<br>[65]<br>[115]<br>[116]<br>[39]<br>[65]<br>[185]<br>[138]<br>[138]<br>[202]<br>[93]<br>[121]<br>[121]<br>[184]<br>[320]<br>[343]<br>[121]<br>[101] |
| NMDA antagonists                               | Kynurenic acid (300 mg/kg)<br>Kynurenic acid (200–300 mg/kg)<br>PEG-SOD + PEG-Catalase (10,000 U/kg)                                                                                                                                                                                                                                                                                                                                                     | 7 days/rat<br>7 days/rat<br>0–3 days/pig                                                                                                                                                                                                                                    | UCO + 2 h 7.7% O <sub>2</sub><br>UCO + 1.5 h 8% O <sub>2</sub><br>30 min BCO + hypotonia u. 15 min 6% O <sub>2</sub>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | post<br>pre (1 h)<br>post                                                                                                                                                       | partial<br>partial<br>no effect                                                                                                                                                                          | [5]<br>[246]<br>[185]                                                                                                                                      |
| AMPA antagonist<br>Glutamate release inhibitor | Deferoxamine (100 mg/kg)<br>Allopurinol (135 mg/kg)<br>U74006F (7.5 mg/kg)<br>U74689F (10 mg/kg)<br>Nitro-L-arginine (2 mg/kg)<br>Nitro-L-arginine (50–100 mg/kg)<br>Dexamethasone (0.01–0.5 mg kg <sup>-1</sup> Tag <sup>-1</sup> )<br>Dexamethasone (0.1 mg/kg)                                                                                                                                                                                        | 7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat                                                                                                                                                                | UCO + 2.25 h 8% O <sub>2</sub><br>UCO + 3 h 8% O <sub>2</sub><br>UCO + 2 h 7.7% O <sub>2</sub><br>UCO + 3 h 8% O <sub>2</sub><br>UCO + 2.5 h 8% O <sub>2</sub><br>UCO + 8% O <sub>2</sub><br>UCO + 3 h 8% O <sub>2</sub>                                                                                                                                                                                                                                                                                                                                                                                              | post (5 min)<br>pre or post (15 min)<br>post or pre and post, pre and post<br>pre and post<br>pre and post<br>pre<br>pre                                                        | partial<br>partial<br>partial<br>no effect<br>partial/no effect<br>partial<br>total                                                                                                                      | [258]<br>[256,257]<br>[14]<br>[65]<br>[129]<br>[330]<br>[16]                                                                                               |
| Iron chelator<br>Free radical scavengers       | Methylprednisolone (0.7 mg/kg)<br>Corticosterone (40 mg/kg)<br>Dexamethasone (0.1 mg/kg)<br>Dexamethasone (0.1 mg/kg)<br>Interleukin-1-receptor-antagonist (100 mg/kg)                                                                                                                                                                                                                                                                                   | 7 days/rat<br>7 days/rat<br>14 days/rat<br>1 month/rat<br>7 days/rat                                                                                                                                                                                                        | UCO + 3 h 8% O <sub>2</sub><br>UCO + 2 h 8% O <sub>2</sub><br>UCO + 1 h 8% O <sub>2</sub><br>UCO + 30 min 8% O <sub>2</sub><br>UCO + 2 h 7.5% O <sub>2</sub>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | pre<br>pre (24 h)<br>pre (24 + 5 h)<br>pre (24 + 5 h)<br>pre and post                                                                                                           | total/no effect<br>partial<br>partial<br>partial<br>no effect<br>partial                                                                                                                                 | [16]<br>[65]<br>[334]<br>[333]<br>[334]<br>[334]<br>[207]                                                                                                  |
| Antiinflammatory                               | Osteogenic protein-1 (50 µg)<br>Antineurophil serum<br>bFGF (100 µg/kg)<br>GM1 (50 mg kg <sup>-1</sup> Tag <sup>-1</sup> )<br>GM1 (30 mg kg <sup>-1</sup> Tag <sup>-1</sup> )<br>Zonisamide (75 mg/kg)<br>Phenytoin (50 mg/kg)<br>boc-aspartyl-fluoromethyl-ketone                                                                                                                                                                                       | 12 days/rat<br>7 days/rat<br>7 days/rat<br>7 days/rat<br>fetal sheep<br>7 days/rat<br>7 days/rat<br>7 days/rat                                                                                                                                                              | BCO + 20 min 8% O <sub>2</sub><br>UCO + 2.25 h 8% O <sub>2</sub><br>UCO + 1.5 h 8% O <sub>2</sub><br>2 h 7% O <sub>2</sub><br>30 min ischemia<br>UCO + 2.5 h 8% O <sub>2</sub><br>UCO + 2.5 h 8% O <sub>2</sub><br>UCO + 2 h 7.5% O <sub>2</sub>                                                                                                                                                                                                                                                                                                                                                                      | pre<br>pre<br>pre (30 min)<br>pre and post<br>pre<br>pre<br>pre<br>post                                                                                                         | partial<br>partial<br>partial<br>partial<br>partial<br>partial<br>partial<br>partial                                                                                                                     | [270]<br>[260]<br>[247]<br>[120]<br>[321]<br>[123]<br>[124]<br>[61]                                                                                        |
| Growth factor<br>Gangliosides                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                 |                                                                                                                                                                                                          |                                                                                                                                                            |
| Anticonvulsants                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                 |                                                                                                                                                                                                          |                                                                                                                                                            |
| Inhibition of caspases                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                 |                                                                                                                                                                                                          |                                                                                                                                                            |




Fig. 15. Incidence of cerebral palsy in very low birth weight children (< 1500 g) at the age of 3 years. Note that the incidence of cerebral palsy in children from women with ante-natal magnesium therapy was much lower than in those without magnesium therapy (7% vs. 36%; \*\*  $P < 0.01$ ) [238].

needs to be demonstrated in multicentre randomised, double-blind studies.

## 11. Conclusion

Perinatal brain damage in the mature fetus is usually brought about by severe intrauterine asphyxia following an acute reduction of the uterine or umbilical circulation. Owing to the acute reduction in oxygen supply, oxidative phosphorylation in the brain comes to a standstill. The  $\text{Na}^+/\text{K}^+$  pump at the cell membrane has no more energy to maintain the ionic gradients. In the absence of a membrane potential, large amounts of calcium ions flow through the voltage-dependent ion channel, down an extreme extra-/intracellular concentration gradient, into the cell. Additionally to the influx of calcium ions into the cells via voltage-dependent calcium channels, calcium also enters the cells through glutamate-regulated ion channels. Current research suggests that the excessive increase in levels of intracellular calcium, so-called calcium overload, leads to cell damage through the activation of proteases, lipases and endonucleases. A second wave of neuronal cell damage occurs during the reperfusion phase. This cell damage is thought to be caused by the post-ischemic inhibition of protein synthesis, release of oxygen radicals, synthesis of NO, inflammatory reactions and an imbalance between the excitatory and inhibitory neurotransmitter systems. Part of the secondary neuronal cell damage may be caused by induction of a kind of cellular suicide programme known as apoptosis. Knowledge of these pathophysiological mechanisms has enabled scientists to develop new thera-

peutic strategies with successful results in animal experiments. Of these i.v. administration of magnesium and post-ischemic induction of cerebral hypothermia may become clinical relevance over the next years.

## References

- [1] A. Abdel-Rahman, J.K. Parks, M.W. Deveraux, R.J. Sokol, W.D. Parker Jr., A.A. Rosenberg, Developmental changes in newborn lamb brain mitochondrial activity and postasphyxial lipid peroxidation, *PSEBM* 209 (1995) 170–177.
- [2] P.G. Aitken, M. Balestrino, G.G. Somjen, NMDA antagonists: lack of protective effect against hypoxic damage in CA1 region of hippocampal slices, *Neurosci. Lett.* 89 (1988) 187–192.
- [3] U.A.S. Al-Khalidi, T.H. Chaglassian, The specific distribution of xanthine oxidase, *J. Biochem.* 97 (1965) 318–320.
- [4] G.W. Albers, M.P. Goldberg, D.W. Choi, Do NMDA antagonists prevent neuronal injury?, *Arch. Neurol.* 49 (1992) 418–420.
- [5] D.I. Altman, R.S.K. Young, S.K. Yagel, Effects of dexamethasone in hypoxic/ischemic brain injury in the neonatal rat, *Biol. Neonate* 46 (1984) 149–156.
- [6] B. Altura, B.M. Altura, Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries, *Neurosci. Lett.* 20 (1980) 323–327.
- [7] M. Amato, J.C. Fauchere, U. Hermann Jr., Coagulation abnormalities in low birth weight infants with peri-intraventricular hemorrhage, *Neuropediatrics* 19 (1988) 154–157.
- [8] A. Ames, R.L. Wright, M. Kowada, J.M. Thurston, G. Majno, Cerebral ischemia: II. The no-reflow phenomenon, *Am. J. Pathol.* 52 (1968) 437–453.
- [9] G. An, T.-N. Lin, X.-S. Liu, J.-J. Xue, Y.-Y. He, Cy. Hsu, Expression of *c-fos* and *c-jun* family genes after focal cerebral ischemia, *Ann. Neurol.* 33 (1993) 457–464.
- [10] P. Andine, A. Lehmann, K. Ellren, E. Wennberg, I. Kjellmer, T. Nielsen, H. Hagberg, The excitatory amino acid antagonist kynurenic acid administered after hypoxic ischemia in neonatal rat offers neuroprotection, *Neurosci. Lett.* 90 (1988) 208–212.
- [11] D. Armstrong, M.G. Norman, Periventricular leukomalacia in neonates. Complications and sequelae, *Arch. Dis. Child.* 49 (1974) 367–375.
- [12] S. Ashwal, P.S. Dale, L.D. Longo, Regional cerebral blood flow: studies in the fetal lamb during hypoxia, hypercapnia, acidosis, and hypertension, *Pediatr. Res.* 18 (1984) 1309–1316.
- [13] S. Ashwal, D.J. Cole, S. Osborne, T.N. Osborne, W.J. Pearce, L-NAME reduces infarct volume in a filament model of transient middle cerebral artery occlusion in the rat pup, *Pediatr. Res.* 38 (1995) 652–656.
- [14] R. Bagenholm, P. Andine, H. Hagberg, Effects of the 21-amino steroid tirilazad mesylate (U74006F) on brain damage and edema after hypoxia-ischemia in the rat, *Pediatr. Res.* 40 (1995) 399–403.
- [15] B.Q. Banker, J.C. Larroche, Periventricular leukomalacia of infancy, *Arch. Neurol.* 7 (1962) 386–410.
- [16] J.D.E. Barks, M. Post, U.I. Tuor, Dexamethasone prevents hypoxic/ischemic brain damage in the neonatal rat, *Pediatr. Res.* 29 (1991) 558–563.
- [17] M.A. Barmada, J. Moossy, R.M. Shuman, Cerebral infarcts with arterial occlusion in neonates, *Ann. Neurol.* 6 (1979) 495–502.
- [18] T. Beck, G.W. Bielenberg, The effects of two 21-aminosteroids on overt infarct size 48 hours after middle cerebral artery occlusion in the rat, *Brain. Res.* 560 (1991) 159–162.
- [19] J.S. Beckman, T.W. Beckman, J. Chen, P.A. Marshall, B.A. Freeman, Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide, *Proc. Natl. Acad. Sci.* 87 (1990) 1620–1624.
- [20] J.S. Beckman, H. Ischiropoulos, J. Chen, Nitric oxide as a mediator

- of superoxide-dependent injury, in: K.J.A. Davies (Ed.), *Oxidative Damage and Repair. Chemical, Biological and Medical Aspects*, Pergamon, Oxford, 1992, 251 pp.
- [21] J.S. Beckman, J. Chen, H. Ischiropoulos, K.A. Conger, Inhibition of nitric oxide synthesis and cerebral protection, in: J. Kriegstein, H. Oberpichler-Schwenk (Eds.), *Pharmacology of Cerebral Ischemia*, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1992, 383 pp.
  - [22] R. Bejar, G. Vigliocco, H. Gramajo, C. Solana, K. Benirschke, C. Berry, R. Coen, Antenatal origin of neurologic damage in newborn infants: II. Multiple gestations, *Am. J. Obstet. Gynecol.* 162 (1990) 1230–1236.
  - [23] F.C. Benedikt, R.C. Lee, *Hibernation and marmot physiology*. Carnegie Institution of Washington, Publication no. 494, Washington, DC, 1938.
  - [24] H. Benveniste, J. Drejer, A. Schousboe, N.M. Diemer, Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis, *J. Neurochem.* 43 (1984) 1369–1374.
  - [25] K. Benirschke, The contribution of placental anastomoses to prenatal twin damage, *Hum. Pathol.* 23 (1992) 1319–1320.
  - [26] D.W. Benson, G.R. Williams, F.C. Spencer, E. Yates, The use of hypothermia after cardiac arrest, *Anesth. Analg.* 38 (1959) 423–428.
  - [27] R. Berger, A. Jensen, J. Kriegstein, J.P. Steigelman, Effects of acute asphyxia on brain energy metabolism in fetal guinea pigs near term, *J. Dev. Physiol.* 16 (1991) 9–11.
  - [28] R. Berger, A. Jensen, J. Kriegstein, J.P. Steigelman, Cerebral energy metabolism in immature and mature guinea pig fetuses during acute asphyxia, *J. Dev. Physiol.* 18 (1992) 125–128.
  - [29] R. Berger, A. Jensen, J. Kriegstein, J.P. Steigelman, Cerebral energy metabolism in fetal guinea pigs during moderate maternal hypoxemia at 0.75 of gestation, *J. Dev. Physiol.* 19 (1993) 193–196.
  - [30] R. Berger, A. Gjedde, J. Heck, E. Müller, J. Kriegstein, A. Jensen, Extension of the 2-deoxyglucose method to the fetus in utero: theory and normal values for the cerebral glucose consumption in fetal guinea pigs, *J. Neurochem.* 63 (1994) 271–279.
  - [31] R. Berger, B. Djuricic, A. Jensen, K.-A. Hossmann, W. Paschen, Ontogenetic differences in energy metabolism and inhibition of protein synthesis in hippocampal slices during in vitro ischemia and 24 h of recovery, *Dev. Brain Res.* 91 (1996) 281–291.
  - [32] R. Berger, B. Djuricic, A. Jensen, K.-A. Hossmann, W. Paschen, Mild hypothermia provides neuroprotection in an in vitro model of fetal cerebral ischemia, *J. Soc. Gynecol. Invest.* 3 (1996) 391.
  - [33] R. Berger, T. Lehmann, J. Karcher, W. Schachenmayr, A. Jensen, Relation between cerebral oxygen delivery and neuronal cell damage in fetal sheep near term, *Reprod. Fertil. Dev.* 8 (1996) 317–321.
  - [34] R. Berger, S. Bender, S. Sefkow, V. Klingmüller, W. Künzel, A. Jensen, Peri/intraventricular haemorrhage: a cranial ultrasound study on 5286 neonates, *Eur. J. Obstet. Gynecol. Reprod. Biol.* 75 (1997) 191–203.
  - [35] R. Berger, A. Gjedde, L. Hargarter, S. Hargarter, J. Kriegstein, A. Jensen, Regional cerebral glucose utilization in immature fetal guinea pigs during maternal isocapnic hypoxemia, *Pediatr. Res.* 42 (1997) 311–316.
  - [36] R. Berger, A. Jensen, K.-A. Hossmann, W. Paschen, No effect of glutamate on metabolic disturbances in hippocampal slices of mature fetal guinea pigs after transient in vitro ischemia, *Dev. Brain Res.* 101 (1997) 49–56.
  - [37] R. Berger, A. Jensen, K.-A. Hossmann, W. Paschen, Effect of mild hypothermia during and after transient in vitro ischemia on metabolic disturbances in hippocampal slices at different stages of development, *Dev. Brain Res.* 105 (1998) 67–77.
  - [38] R. Berger, A. Jensen, W. Paschen, Metabolic disturbances in hippocampal slices of fetal guinea pigs during and after oxygen-glucose deprivation: is nitric oxide involved?, *Neurosci. Lett.* 245 (1998) 163–166.
  - [39] R. Berger, T. Lehmann, J. Karcher, Y. Garnier, A. Jensen, Low dose flunarizine protects the fetal brain from ischemic injury in sheep, *Pediatr. Res.* 44 (1998) 277–282.
  - [40] A. Bieganski, A.B. Joseph, Development of HU-211 as a neuroprotectant for ischemic brain damage, *Neurol. Res.* 17 (1995) 275–280.
  - [41] W.G. Bigelow, W.K. Lindsay, R.C. Harrison, Oxygen transport and utilization in dogs at low body temperatures, *Am. J. Physiol.* 160 (1950) 125–137.
  - [42] T.V.P. Bliss, G.L. Collingridge, A synaptic model of memory: long term potentiation in the hippocampus, *Nature* 361 (1993) 31–39.
  - [43] R.M. Blumberg, E.B. Cady, J.S. Wigglesworth, J.E. McKenzie, A.D. Edwards, Relation between delayed impairment of cerebral energy metabolism and infarction following transient focal hypoxia-ischaemia in the developing brain, *Exp. Brain Res.* 113 (1997) 130–137.
  - [44] K.S. Blumenfeld, F.A. Welsh, V.A. Harris, M.A. Pesenson, Regional expression of c-fos and heat shock protein-70 mRNA following hypoxia-ischemia in immature rat brain, *J. Cereb. Blood Flow Metab.* 12 (1992) 987–995.
  - [45] W. Bodschi, K. Takahashi, A. Barbier, B. Grosse Ophoff, K.-A. Hossmann, Cerebral protein synthesis and ischemia, *Prog. Brain Res.* 63 (1985) 197–210.
  - [46] C. Bordarier, O. Robain, Microgyric necrotic cortical lesions in twin fetuses — original cerebral damage consecutive to twinning, *Brain Dev.* 14 (1992) 174–178.
  - [47] E.H. Botterell, W.M. Loughheed, J.W. Scott, S.L. Vandewater, Hypothermia, and interruption of carotid, or carotid and vertebral circulation, in the surgical management of intracranial aneurysms, *J. Neurosurg.* 13 (1956) 1–42.
  - [48] A.K. Brown, J.A. McGarry, Eclampsia with hyperpyrexia: a case treated by total body cooling, *Scott. Med. J.* 6 (1961) 311–313.
  - [49] A.M. Buchan, Do NMDA antagonists prevent neuronal injury?, *Arch. Neurol.* 49 (1992) 420–421.
  - [50] A.M. Buchan, S.Z. Gertler, Z.G. Huang, H. Li, K.E. Chaundy, D. Xue, Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide, *Neuroscience* 61 (1994) 1–11.
  - [51] O. Bumke, O. Foerster, *Handbuch der Neurologie*, Band XVI. Verlag von Julius Springer, Berlin, 1936.
  - [52] J. Busciglio, B.A. Yankner, Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro, *Nature* 378 (1995) 776–779.
  - [53] R. Busto, W.D. Dietrich, M.Y.T. Globus, I. Valdés, P. Scheinberg, M.D. Ginsberg, Small differences in intras ischemic brain temperature critically determine the extent of ischemic neuronal injury, *J. Cereb. Blood Flow Metab.* 7 (1987) 729–738.
  - [54] R. Busto, M.Y.T. Globus, W.D. Dietrich, E. Martinez, I. Valdés, M.D. Ginsberg, Effect of mild hypothermia on ischemic-induced release of neurotransmitters and free fatty acids in rat brain, *Stroke* 20 (1989) 904–910.
  - [55] M. Caldwell, M. O'Neill, B. Earley, B. Leonard, NG-nitro-L-arginine protects against ischaemia-induced increases in nitric oxide and hippocampal neuro-degeneration in the gerbil, *Eur. J. Pharmacol.* 260 (1994) 191–200.
  - [56] X. Cao, J.W. Phillis, The free radical scavenger, alpha-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils, *Free Radical Res.* 23 (1995) 365–370.
  - [57] M. Cardell, F. Boris-Miller, T. Wieloch, Hypothermia prevents the ischemia-induced translocation and inhibition of protein kinase C in the rat striatum, *J. Neurochem.* 57 (1991) 1814–1817.
  - [58] A.J. Carter, R.E. Mueller, Activation of excitatory amino acid receptors cannot alone account for anoxia-induced impairment of protein synthesis in rat hippocampal slices, *J. Neurochem.* 57 (1991) 888–896.
  - [59] M. Cavazutti, T.E. Duffy, Regulation of local cerebral blood flow in normal and hypoxic newborn dogs, *Ann. Neurol.* 11 (1982) 247–257.
  - [60] P.H. Chan, G.Y. Yang, S.F. Chen, Cold-induced brain edema and

- infarction are reduced in transgenic mice overexpressing CuZn-superoxide dismutase, *Ann. Neurol.* 29 (1991) 482–486.
- [61] Y. Cheng, M. Deshmukh, A. D'Costa, J.A. Demaro, J.M. Gidday, A. Shah, Y. Sun, M.F. Jacquin, E.M. Johnson, D.M. Holtzman, Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic–ischemic brain injury, *J. Clin. Invest.* 101 (1998) 1992–1999.
  - [62] D.W. Choi, Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage, *TINS* 11 (1988) 465–469.
  - [63] D.W. Choi, Excitotoxic cell-death, *J. Neurobiol.* 23 (1992) 1261–1276.
  - [64] M. Chopp, R. Knight, C.D. Tidwell, J.A. Helpert, E. Brown, K.M.A. Welch, The metabolic effects of mild hypothermia on global cerebral ischemia and recirculation in the cat: comparison to normothermia and hypothermia, *J. Cereb. Blood Flow Metab.* 9 (1989) 141–148.
  - [65] P.D. Chumas, M.R. Del Bigio, J.M. Drake, U.I. Tuor, A comparison of the protective effect of dexamethasone to other potential prophylactic agents in a neonatal rat model of cerebral hypoxia/ischemia, *J. Neurosurg.* 79 (1993) 414–420.
  - [66] S.B. Churn, W.C. Taft, M.S. Billingsley, R.E. Blair, R.J. DeLorenzo, Temperature modulation of ischemic neuronal death and inhibition of calcium/calmodulin-dependent protein kinase II in gerbils, *Stroke* 21 (1990) 1715–1721.
  - [67] C. Coimbra, T. Wieloch, Moderate hypothermia mitigates neuronal damage in the rat brain when initiated several hours following transient ischemia, *Acta Neuropathol.* 87 (1994) 325–331.
  - [68] C.W. Cotman, D.T. Monaghan, Anatomical organization of excitatory amino acid receptors and their properties, *Adv. Exp. Med. Biol.* 203 (1986) 237–252.
  - [69] D.B. Cotton, C.A. Janusz, R.F. Berman, Anticonvulsant effects of magnesium sulphate on hippocampal seizures: therapeutic implications in pre-eclampsia–eclampsia, *Am. J. Obstet. Gynecol.* 166 (1992) 1127–1136.
  - [70] J.T. Coyle, S.J. Enna, Neurochemical aspects of the ontogenesis of GABAergic neurons in the rat brain, *Brain Res.* 111 (1976) 119–133.
  - [71] T.V. Craig, W. Hunt, R. Atkinson, Hypothermia — its use in severe carbon monoxide poisoning, *N. Engl. J. Med.* 261 (1976) 854–856.
  - [72] D.P. Cruikshank, R.M. Pitkin, W.A. Reynolds, G.A. Williams, G.K. Hargis, Effects of magnesium sulfate treatment on perinatal calcium metabolism, *Am. J. Obstet. Gynecol.* 134 (1979) 243–249.
  - [73] R. Crumrin, A. Thomas, P. Morgan, Attenuation of p53 expression protects against focal ischemic damage in transgenic mice, *J. Cereb. Blood Flow Metab.* 14 (1994) 887–891.
  - [74] T. Dalkara, M.A. Moskowitz, The complex role of nitric oxide in the pathophysiology of focal cerebral ischemia, *Brain Pathol.* 4 (1994) 49–57.
  - [75] M. Damska, M. Laure-Kamionowska, B. Schmidt-Sidor, Early and late neuropathological changes in white matter damage, *J. Child. Neurol.* 4 (1989) 291–298.
  - [76] K.J.A. Davies, Protein damage and degradation by oxygen radicals: I. General aspects, *J. Biol. Chem.* 262 (1987) 9895–9901.
  - [77] K.J.A. Davies, A.L. Goldberg, Oxygen radicals stimulate intracellular proteolysis and lipid peroxidation by independent mechanisms in erythrocytes, *J. Biol. Chem.* 262 (1987) 8220–8226.
  - [78] D.A. Dawson, Nitric oxide and focal ischemia: multiplicity of actions and diverse outcome, *Cerebrovasc. Brain Metab. Rev.* 6 (1994) 299–324.
  - [79] J.L. De Reuck, Cerebral angioarchitecture and perinatal brain lesions in premature and full-term infants, *Acta Neurol. Scand.* 70 (1984) 391–395.
  - [80] S.M. de la Monte, F.I. Hsu, E.T. Hedley-Whyte, W. Kupsky, Morphometric analysis of the human infant brain: effects of intraventricular hemorrhage and periventricular leukomalacia, *J. Child. Neurol.* 5 (1990) 101–110.
  - [81] L.S. de Vries, J.S. Wigglesworth, R. Regev, L.M. Dubowitz, Evolution of periventricular leukomalacia during the neonatal period and infancy: correlation of imaging and postmortem findings, *Early Hum. Dev.* 17 (1988) 205–219.
  - [82] E. Dell'Anna, Y. Chen, F. Loidl, K. Andersson, J. Luthman, M. Gojny, R. Rawal, T. Lindgren, M. Herrera-Marschitz, Short-term effects of perinatal asphyxia studied with fos-immunocytochemistry and in vivo microdialysis in the rat, *Exp. Neurol.* 131 (1995) 279–287.
  - [83] W.D. Dietrich, R. Busto, M. Halley, I. Valdés, The importance of brain temperature in alterations of the blood-brain barrier following cerebral ischemia, *J. Neuropathol. Exp. Neurol.* 49 (1990) 486–497.
  - [84] B. Djuricic, G. Rihn, W. Paschen, K.-A. Hossmann, Protein synthesis in the hippocampal slice: transient inhibition by glutamate and lasting inhibition by ischemia, *Metab. Brain Dis.* 9 (1994) 235–247.
  - [85] M. Dragunow, E. Beilharz, E. Sirimanne, P. Lawlor, C.E. Williams, R. Bravo, P.D. Gluckman, Immediate-early gene protein expression in neurons undergoing delayed death, but not necrosis, following hypoxic–ischemic injury to the young rat brain, *Mol. Brain Res.* 25 (1994) 19–33.
  - [86] C.G. Drake, H.W.K. Barr, J.C. Coles, N.F. Gergely, The use of extracorporeal circulation and profound hypothermia in the treatment of ruptured intracranial aneurysm, *J. Neurosurg.* 21 (1964) 575–581.
  - [87] E. Dux, U. Oeschlies, C. Wiessner, K.-A. Hossmann, Glutamate-induced ribosomal disaggregation and ultrastructural changes in rat cortical neuronal culture — protective effect of horse serum, *Neurosci. Lett.* 141 (1992) 173–176.
  - [88] S.J. East, J. Garthwaite, NMDA receptor activation in rat hippocampus induces cGMP formation through the L-arginine–nitric oxide pathway, *Neurosci. Lett.* 123 (1991) 17–19.
  - [89] W. El-Deiry, T. Tokino, V. Velculescu, D. Levy, R. Parsons, J. Trent, D. Lin, W. Mercer, K. Kinzler, B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression, *Cell* 75 (1993) 817–825.
  - [90] A. Etzioni, Adhesion molecules — their role in health and disease, *Pediatr. Res.* 39 (1996) 191–198.
  - [91] V. Fellman, K.O. Raivio, Reperfusion injury as the mechanism of brain damage after perinatal asphyxia, *Pediatr. Res.* 41 (1996) 599–606.
  - [92] D.M. Ferriero, H.Q. Soberano, R.P. Simon, F.R. Sharp, Hypoxia–ischemia induces heat shock protein-like (HSP72) immunoreactivity in neonatal rat brain, *Dev. Brain Res.* 53 (1990) 145–150.
  - [93] L.M. Ford, P.R. Sanberg, A.B. Norman, M.H. Fogelson, MK-801 prevents hippocampal neurodegeneration in neonatal hypoxic–ischemic rats, *Arch. Neurol.* 46 (1989) 1090–1096.
  - [94] I. Fridovich, The biology of the oxygen radicals. The superoxide radical is an agent of oxygen toxicity; superoxide dismutases provide an important defense, *Science* 201 (1978) 875–880.
  - [95] I. Fridovich, Superoxide radical: an endogenous toxicant, *Annu. Rev. Pharmacol. Toxicol.* 23 (1983) 239–257.
  - [96] R.L. Friede, *Developmental Neuropathology*, Springer-Verlag, New York, 1989.
  - [97] M. Funato, H. Tamai, K. Noma, T. Kurita, Y. Kajimoto, Y. Yoshioka, S. Shimada, Clinical events in association with timing of intraventricular hemorrhage in preterm infants, *J. Pediatr.* 121 (1992) 614–619.
  - [98] Y. Garnier, T. Löbber, A. Jensen, R. Berger, Lack of neuroprotection by glutamate antagonist lubeluzole after transient global cerebral ischemia in fetal sheep, *J. Soc. Gynecol. Invest.* 5 (1998) F513.
  - [99] J. Garthwaite, Glutamate, nitric oxide and cell–cell signaling in the nervous system, *Trends Neurosci.* 14 (1991) 60–67.

- [100] J. Gehrmann, P. Bonnekoh, T. Miyazawa, U. Oschlies, E. Duz, K.-A. Hosmann, G.W. Kreutzberg, The microglia reaction in the rat hippocampus following global ischemia: immunoelectron microscopy, *Acta Neuropathol.* 84 (1992) 588–595.
- [101] E. Gilland, M. Puka-Sundvall, P. Andine, E. Bona, H. Hagberg, Hypoxic-ischemic injury in the neonatal rat brain: effects of pre- and post-treatment with the glutamate release inhibitor BW1003C87, *Dev. Brain Res.* 83 (1994) 79–84.
- [102] F.H. Gilles, A. Leviton, E.C. Dooling, *The Developing Human Brain: Growth and Epidemiologic Neuropathology*. John Wright PSG, Boston, 1983.
- [104] M.D. Ginsberg, M.Y.T. Globus, E. Martinez, T. Morimoto, B. Lin, H. Schnipperin, O.F. Alonso, R. Busto, Oxygen radical and excitotoxic processes in brain ischemia and trauma, in: J. Kriegstein, H. Oberpichler-Schwenk (Eds.), *Pharmacology of Cerebral Ischemia*, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1994, 255 pp.
- [105] M.Y.T. Globus, R. Busto, W.D. Dietrich, E. Martinez, I. Valdés, M.D. Ginsberg, Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis, *J. Neurochem.* 51 (1988) 1455–1464.
- [106] M.Y.T. Globus, R. Busto, W.D. Dietrich, M.D. Ginsberg, The protective effect of intraischemic mild cerebral hypothermia is associated with inhibition of extracellular glutamate release during ischemia, *Ann. Neurol.* 24 (1988) 127–128.
- [107] R.N. Goldberg, D. Chung, S.L. Goldman, E. Bancalari, The association of rapid volume expansion and intraventricular hemorrhage in the preterm infant, *J. Pediatr.* 96 (1980) 1060–1063.
- [108] J.M. Goplerud, O.P. Mishra, M. Delivoria-Papadopoulos, Brain cell membrane dysfunction following acute asphyxia in newborn piglets, *Biol. Neonate* 61 (1992) 33–41.
- [109] K. Goto, A. Ishige, K. Sekiguchi, S. Iizuka, A. Sugimoto, M. Yuzurihara, M. Aburada, E. Hosoya, K. Kogure, Effects of cycloheximide on delayed neuronal death in rat hippocampus, *Brain Res.* 534 (1990) 299–302.
- [110] D.N. Granger, Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury, *Am. J. Physiol.* 255 (1988) H1269–H1275.
- [111] E.J. Green, W.D. Dietrich, F. van Dijk, R. Busto, C.G. Markgraf, P.M. McCabe, M.D. Ginsberg, N. Schneiderman, Protective effect of brain hypothermia on behavior and histopathology following global cerebral ischemia in rats, *Brain Res.* 580 (1992) 197–204.
- [112] K.W. Green, T.C. Key, R. Coen, R. Resnik, The effects of maternally administered magnesium sulfate on the neonate, *Am. J. Obstet. Gynecol.* 146 (1983) 29–33.
- [113] J.K. Grether, K.B. Nelson, Maternal infection and cerebral palsy in infants of normal birth weight, *JAMA* 278 (1997) 207–211.
- [114] J.K. Grether, J. Hoogstrate, S. Selvin, K.B. Nelson, Magnesium sulfate toxicology and risk of neonatal death, *Am. J. Obstet. Gynecol.* 178 (1998) 1–6.
- [115] A.J. Gunn, T. Mydlar, L. Bennet, R.L.M. Faull, S. Gorter, C. Cook, B.M. Johnston, P.D. Gluckman, The neuroprotective actions of a calcium antagonist, flunarizine, in the infant rat, *Pediatr. Res.* 25 (1989) 573–576.
- [116] A.J. Gunn, C.E. Williams, E.C. Mallard, W.K.M. Tan, P.D. Gluckman, Flunarizine, a calcium channel antagonist, is partially prophylactically neuroprotective in hypoxic/ischemic encephalopathy in the fetal sheep, *Pediatr. Res.* 35 (1994) 657–663.
- [117] A.J. Gunn, T.R. Gunn, H.H. de Haan, C.E. Williams, P.D. Gluckman, Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs, *J. Clin. Invest.* 99 (1997) 248–256.
- [118] A.J. Gunn, P.D. Gluckman, T.R. Gunn, Selective head cooling in newborn infants after perinatal asphyxia: a safety study, *Pediatrics* 102 (1998) 885–892.
- [119] A.J. Gunn, T.R. Gunn, M.I. Gunning, C.E. Williams, P.D. Gluckman, Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep, *Pediatrics* 102 (1998) 1098–1106.
- [120] M. Hadjiconstantinou, A.J. Yates, N.H. Neff, Hypoxia-induced neurotransmitter deficits in neonatal rats are partially corrected by exogenous GM1 ganglioside, *J. Neurochem.* 55 (1990) 864–869.
- [121] H. Hagberg, E. Gilland, N.H. Diemer, P. Andine, Hypoxia-ischemia in the neonatal rat brain: histopathology after post treatment with NMDA and non-NMDA receptor antagonists, *Biol. Neonate* 66 (1994) 205–213.
- [122] T. Hai, T. Curran, Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity, *Proc. Natl. Acad. Sci. U.S.A.* 88 (1991) 3720–3724.
- [123] T. Hajakawa, Y. Hamada, T. Maihara, H. Hattori, H. Mikawa, Phenytoin reduces neonatal hypoxic/ischemic brain damage in rats, *Life Sci.* 54 (1994) 387–392.
- [124] T. Hajakawa, Y. Higuchi, H. Nigami, H. Hattori, Zonisamide reduces hypoxic/ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect, *Eur. J. Pharmacol.* 257 (1994) 131–136.
- [125] E.D. Hall, J.M. Braughler, P.A. Yonkers, S.L. Smith, K.L. Linseman, E.D. Means, H.M. Scherch, P.F. Von Voigtlander, R.A. Lahti, E.J. Jacobsen, U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia, *J. Pharmacol. Exp. Ther.* 258 (1991) 688–694.
- [126] J.M. Hallenbeck, A.J. Dutka, T. Tanishima, P.M. Kochanek, K.K. Kumaroo, C.B. Thompson, T.P. Obrenovitch, T.P. Contreras, Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period, *Stroke* 17 (1986) 246–253.
- [127] B. Halliwell, J.M.C. Gutteridge, Oxygen radicals and the nervous system, *Trends Neurosci.* 8 (1985) 22–26.
- [128] B. Halliwell, J.M.C. Gutteridge, C.E. Cross, Free radicals, antioxidants, and human disease: where are we now?, *J. Lab. Clin. Med.* 199 (1992) 599–620.
- [129] Y. Hamada, T. Hayakama, H. Hattori, H. Mikawa, Inhibitor of nitric oxide synthesis reduces hypoxic/ischemic brain damage in the neonatal rat, *Pediatr. Res.* 35 (1994) 10–14.
- [130] J. Hamada, J.H. Greenberg, S. Croul, T.M. Dawson, M. Reivich, Effects of central inhibition of nitric oxide synthase on focal cerebral ischemia in rats, *J. Cereb. Blood Flow Metab.* 15 (1995) 779–786.
- [131] G. Hambleton, J.S. Wigglesworth, Origin of intraventricular haemorrhage in the preterm infant, *Arch. Dis. Child.* 51 (1976) 651–659.
- [132] P.R. Hansen, Role of neutrophils in myocardial ischemia and reperfusion, *Circulation* 91 (1995) 1872–1885.
- [133] A.J. Hansen, Effect of anoxia on ion distribution in the brain, *Physiol. Rev.* 65 (1985) 101–148.
- [134] J. Harper, G. Adami, N. Wei, K. Keyomarsi, S. Elledge, The p21 CDK-interacting protein Cip1 is a potent inhibitor of cyclin dependent kinases, *Cell* 75 (1993) 805–816.
- [135] J.F. Hartmann, R.A. Becker, M.M. Cohen, Cerebral ultrastructure in experimental hypoxia and ischemia, *Monogr. Neurol. Sci.* 1 (1973) 50–64.
- [136] K. Hasegawa, H. Yoshioka, T. Sawada, H. Nishikawa, Direct measurement of free radicals in the neonatal mouse brain subjected to hypoxia: an electron spin resonance spectroscopic study, *Brain Res.* 607 (1993) 161–166.
- [137] K. Hasegawa, L. Litt, M.T. Espanol, G.A. Gregory, F.R. Sharp, P.H. Chan, Effects of neuroprotective dose of fructose-1,6-bisphosphate on hypoxia-induced expression of c-fos and hsp70 mRNA in neonatal rat cerebrotical slices, *Brain Res.* 750 (1997) 1–10.
- [138] H. Hattori, A.M. Morin, P.H. Schwartz, D.G. Fujikawa, C.G. Waterlain, Posthypoxic treatment with MK-801 reduces hypoxic/ischemic damage in the neonatal rat, *Neurology* 39 (1989) 713–718.
- [139] M.A. Helfaer, J.R. Kirsch, R.J. Traystman, Radical scavengers:

- penetration into brain following ischemia and reperfusion, in: J. Krieglstein, H. Oberpichler-Schwenk (Eds.), *Pharmacology of Cerebral Ischemia*, Medpharm Scientific Publishers, Stuttgart, 1994, 297 pp.
- [140] L.A. Hernandez, M.B. Grisham, B. Twohig, K.E. Arfors, J.M. Harlan, D.N. Granger, Role of neutrophils in ischemia–reperfusion-induced microvascular injury, *Am. J. Physiol.* 253 (1987) H699–H703.
- [141] Y. Higuchi, H. Hattori, R. Hattori, K. Furusho, Increased neurons containing neuronal nitric oxide synthase in the brain of hypoxic–ischemic neonatal rat model, *Brain Dev.* 18 (1996) 369–375.
- [142] Y. Higuchi, H. Hattori, T. Kume, M. Tsuji, A. Akaike, K. Furusho, Increase in nitric oxide in the hypoxic–ischemic neonatal rat brain and suppression by 7-nitroindazole and aminoguanidine, *Eur. J. Pharmacol.* 342 (1998) 47–49.
- [143] A. Hill, J.M. Perlman, J.J. Volpe, Relationship of pneumothorax to occurrence of intraventricular hemorrhage in the premature newborn, *Pediatrics* 69 (1982) 144–149.
- [144] P.L. Hope, S.J. Gould, S. Howard, P.A. Hamilton, A.M. Costello, E.O. Reynolds, Precision of ultrasound diagnosis of pathologically verified lesions in the brains of very preterm infants, *Dev. Med. Child Neurol.* 30 (1988) 457–471.
- [145] K.-A. Hossmann, P. Kleihues, Reversibility of ischemic brain damage, *Arch. Neurol.* 29 (1973) 375–384.
- [146] K.-A. Hossmann, R. Widmann, C. Wiessner, E. Dux, B. Djuricic, G. Röhn, Protein synthesis after global cerebral ischemia and selective vulnerability, in: J. Krieglstein, H. Oberpichler-Schwenk (Eds.), *Pharmacology of Cerebral Ischemia*, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1992, 289 pp.
- [147] K.-A. Hossmann, Ischemia-mediated neuronal injury, *Resuscitation* 26 (1993) 225–235.
- [148] K.-A. Hossmann, Mechanisms of ischemic injury: is glutamate involved? in: J. Krieglstein, H. Oberpichler-Schwenk (Eds.), *Pharmacology of Cerebral Ischemia*, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1994, 239 pp.
- [149] S. Houdou, S. Takashima, K. Takeshita, S. Ohta, Infantile subcortical leukohypodensity demonstrated by computed tomography, *Pediatr. Neurol.* 4 (1988) 165–167.
- [150] D.A. Howell, J.G. Stratford, J. Posnikoff, Prolonged hypothermia in treatment of massive cerebral haemorrhage. A preliminary report, *Can. Med. Assoc. J.* 75 (1956) 388–394.
- [151] Z. Huang, P.L. Huang, N. Panahian, T. Dalkara, M.C. Fishman, M.A. Moskowitz, Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase, *Science* 265 (1994) 1883–1885.
- [152] S. Hudome, C. Palmer, R.L. Roberts, D. Mauger, C. Housman, J. Towfighi, The role of neutrophils in the production of hypoxic–ischemic brain injury in the neonatal rat, *Pediatr. Res.* 41 (1996) 607–616.
- [153] R.W. Hurst, S.R. Kerns, J. McIlhenny, T.S. Park, W.S. Cail, Neonatal dural venous sinus thrombosis associated with central venous catheterization: CT and MR studies, *J. Comput. Assist. Tomogr.* 13 (1989) 504–507.
- [154] H. Ischiropoulos, L. Zhu, J. Chen, M. Tsai, J.C. Martin, C.D. Smith, J.S. Beckman, Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase, *Arch. Biochem. Biophys.* 298 (1992) 1–7.
- [155] L. Jayaraman, C. Prives, Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus, *Cell* 81 (1995) 1021–1029.
- [156] A. Jensen, M. Hohmann, W. Künzel, Dynamic changes in organ blood flow and oxygen consumption during acute asphyxia in fetal sheep, *J. Dev. Physiol.* 9 (1987) 543–559.
- [157] A. Jensen, R. Berger, Fetal circulatory responses to oxygen lack, *J. Dev. Physiol.* 16 (1991) 181–207.
- [158] A. Jensen, V. Klingmüller, W. Künzel, S. Sefkow, Das Hirnblutungsrisiko bei Früh- und Reifgeborenen, *Geburtsh. u. Frauenheilk.* 52 (1992) 6–20.
- [159] F.E. Jensen, C.D. Applegate, D. Holtzman, T.R. Belin, J.L. Burchfiel, Epileptogenic effects of hypoxia on immature rodent brain, *Ann. Neurol.* 29 (1991) 629–637.
- [160] F.E. Jensen, H. Blume, S. Alvarado, I. Firkusny, C. Geary, NBQX blocks the acute and late epileptogenic effects of perinatal hypoxia, *Epilepsia* 36 (1995) 966–972.
- [161] F.E. Jensen, Perinatal hypoxic–ischemic brain injury: maturation-dependent relation to epilepsy, *MRDD Res. Rev.* 3 (1997) 85–95.
- [162] K. Jiang, S. Kim, S. Murphy, D. Song, A. Pastuszko, Effect of hypoxia and reoxygenation on regional activity of nitric oxide synthase in brain of newborn piglets, *Neurosci. Lett.* 206 (1996) 199–203.
- [163] H. Johansson, B.K. Siesjö, Cerebral blood flow and oxygen consumption in the rat in hypoxic hypoxia, *Acta Physiol. Scand.* 93 (1975) 269–276.
- [164] G.N. Johnson, R.J. Palahniuk, W.A. Tweed, Regional cerebral blood flow changes during severe fetal asphyxia produced by slow partial umbilical cord compression, *Am. J. Obstet. Gynecol.* 135 (1997) 48–52.
- [165] I.S. Kass, P. Lipton, Calcium and long term transmission damage following anoxia in dentate gyrus and CA1 regions of the rat hippocampal slice, *J. Physiol.* 37 (1986) 313–324.
- [166] I.S. Kass, J.E. Cotrell, G. Cambers, Magnesium and cobalt, not nimodipine, protect neurons against anoxic damage in the rat hippocampal slice, *Anesthesiology* 69 (1988) 710–715.
- [167] M. Kastan, Q. Zan, W. El-Deiry, F. Carrier, T. Jacks, W. Walsh, B. Plunkett, B. Vogelstein, A.J. Fornace, A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia–telangiectasia, *Cell* 71 (1992) 587–597.
- [168] M. Khrestchatsky, S. Timsit, S. Rivera, E. Tremblay, Y. Ben-Ari, Neuronal death and damage repair: roles of protooncogenes and cell cycle-related proteins, in: J. Krieglstein (Ed.), *Pharmacology of Cerebral Ischemia*, Medpharm Scientific Publishers, Stuttgart, 1996, 41 pp.
- [169] Y. Kinuta, M. Kimura, Y. Itokawa, M. Ishikawa, H. Kikuchi, Changes in xanthine oxidase in ischemic rat brain, *J. Neurosurg.* 71 (1989) 417–420.
- [170] T. Kirino, K. Sano, Final structure of delayed neuronal cell death following ischemia in gerbil hippocampus, *Acta Neuropathol. (Berlin)* 62 (1984) 209–218.
- [171] P. Kleihues, K.-A. Hossmann, A.E. Pegg, K. Kobayashi, V. Zimmermann, Resuscitation of the monkey brain after one hour of complete ischemia: III. Indications of metabolic recovery, *Brain Res.* 95 (1975) 61–73.
- [172] N.W. Knuckey, D. Palm, M. Primano, M.H. Epstein, C.E. Johanson, N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats, *Stroke* 26 (1995) 305–310.
- [173] S. Kobayashi, F.A. Welsh, Regional alterations of ATP and heat-shock protein-72 mRNA following hypoxia–ischemia in neonatal rat brain, *J. Cereb. Blood Flow Metab.* 15 (1995) 1047–1056.
- [174] A. Kochhar, J.A. Zivin, P.D. Lyden, V. Mazarrella, Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia, *Arch. Neurol.* 45 (1988) 148–153.
- [175] R.S. Kramer, A.P. Sanders, A.M. Lesage, The effect of profound hypothermia on preservation of cerebral ATP content during circulatory arrest, *J. Thorac. Cardiovasc. Surg.* 56 (1968) 699–709.
- [176] K.C. Kuban, F.H. Gilles, Human telencephalic angiogenesis, *Ann. Neurol.* 17 (1985) 539–548.
- [177] J.W. Kuluz, R.J. Prado, W.D. Dietrich, C.L. Schleien, B.D. Watson, The effect of nitric oxide synthase inhibition on infarct volume after reversible focal cerebral ischemia in conscious rats, *Stroke* 24 (1993) 2023–2029.
- [178] S. Kure, T. Tominaga, T. Yoshimoto, K. Tada, K. Narisawa, Glutamate triggers internucleosomal DNA cleavage in neuronal cells, *Biochem. Biophys. Res. Commun.* 179 (1991) 39–45.
- [179] J.C. Larroche, *Developmental Pathology of the Neonate*, Excerpta Medica, New York, 1977.

- [180] J.C. Larroche, Intraventricular hemorrhage in the premature neonate, in: R. Korbkin, C. Guilleminault (Eds.), *Advances in Perinatal Neurology*, Vol. 1., SP Medical and Scientific Books, New York, 1979.
- [181] J.C. Larroche, Fetal encephalopathies of circulatory origin, *Biol. Neonate* 50 (1986) 61–74.
- [182] N.A. Lassen, Brain extracellular pH: the main factor controlling cerebral blood flow, *Scan. J. Clin. Lab. Invest.* 22 (1968) 247–251.
- [183] M. Lauritzen, A.J. Hansen, The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression, *J. Cereb. Blood Flow Metab.* 12 (1992) 223–229.
- [184] M.H. Le Blanc, V. Vig, B. Smith, C.C. Parker, O.B. Evans, E.E. Smith, MK-801 does not protect against hypoxic/ischemic brain injury in piglets, *Stroke* 22 (1991) 1270–1275.
- [185] M.H. Le Blanc, V. Vig, T. Ranhawa, E.E. Smith, C.C. Parker, E.G. Brown, Use of polyethylene glycol-bound superoxide dismutase, polyethylene glycol-bound catalase, and nimodipine to prevent hypoxic ischemic injury to the brain of newborn pigs, *Crit. Care Med.* 21 (1993) 252–259.
- [186] S. Lee, B. Elenbaas, A. Levine, p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion deletion mismatches, *Cell* 81 (1995) 1013–1020.
- [187] D. Lekieffre, O. Ghribi, J. Callebort, M. Allix, M. Plotikine, R.G. Boulou, Inhibition of glutamate release in rat hippocampus by kynurenic acid does not protect CA1 cells from forebrain ischemia, *Brain Res.* 592 (1992) 333–337.
- [188] F.J. Lewis, M. Taufic, Closure of atrial septal defects with aid of hypothermia: experimental accomplishments and the report of one successful case, *Surgery* 33 (1953) 52–59.
- [189] Y. Li, M. Chopp, Z. Zhang, C. Zaloga, L. Niewenhuis, S. Gautam, p53 immunoreactive protein and p53 mRNA expression after transient middle cerebral artery occlusion in rats, *Stroke* 25 (1994) 849–856.
- [190] Y. Li, M. Chopp, Z.G. Zhang, C. Zaloga, Induction of DNA fragmentation after 10 to 120 minutes of focal cerebral ischemia in rats, *Stroke* 26 (1995) 1252–1258.
- [191] Y. Lin, J.W. Phillips, Oxypurinol reduces focal ischemia brain injury in the rat, *Neurosci. Lett.* 126 (1991) 187–190.
- [192] M.D. Linnik, P. Zahos, M.D. Geschwind, H.J. Federoff, Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia, *Stroke* 26 (1995) 1670–1675.
- [193] P.J. Lipsitz, The clinical and biochemical effects of excess magnesium in the newborn, *Pediatrics* 47 (1971) 501–509.
- [194] L.D. Longo, Hypoxia–ischaemia and the developing brain: hypotheses regarding the pathophysiology of fetal–neonatal brain damage, *Br. J. Obstet. Gynaecol.* 104 (1997) 652–662.
- [195] H.C. Lou, N.A. Lassen, W.A. Tweed, G. Johnson, M. Jones, R.J. Palahniuk, Pressure passive cerebral blood flow and breakdown of the blood-brain barrier in experimental fetal asphyxia, *Acta Paediatr. Scand.* 68 (1979) 57–63.
- [196] H.C. Lou, W.A. Tweed, J.M. Davies, Preferential blood flow increase to the brain stem in moderate neonatal hypoxia: reversal by naloxone, *Eur. J. Pediatr.* 144 (1985) 225–227.
- [197] W.M. Loughheed, W.H. Sweet, J.C. White, W.R. Brewster, The use of hypothermia in surgical treatment of cerebral vascular lesions. A preliminary report, *J. Neurosurg.* 12 (1955) 240–255.
- [198] B.A. Lupton, A. Hill, M.F. Whitfield, C.J. Carter, L.D. Wadsworth, E.H. Roland, Reduced platelet count as a risk factor for intraventricular hemorrhage, *Am. J. Dis. Child.* 142 (1988) 1222–1224.
- [199] R.E. Lynch, I. Fridovich, Permeation of erythrocyte stroma by superoxide radicals, *J. Biol. Chem.* 253 (1978) 4697–4699.
- [200] X.-L. Ma, P.S. Tsao, A.M. Lefer, Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion, *J. Clin. Invest.* 88 (1991) 1237–1243.
- [201] A.B. MacDermott, M.L. Mayer, G.L. Westbrook, S.J. Smith, J.L. Barker, NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons, *Nature* 321 (1986) 519–522.
- [202] J.W. McDonald, F.S. Silverstein, M.W. Johnson, MK-801 protects the neonatal brain from hypoxic/ischemic damage, *Eur. J. Pharmacol.* 140 (1987) 359–361.
- [203] J. Maher, V. Hachinski, Hypothermia as a potential treatment for cerebral ischemia, *Cerebrovasc. Brain Metab. Rev.* 5 (1993) 277–300.
- [204] F.L. Mannino, D.A. Trauner, Stroke in neonates, *J. Pediatr.* 102 (1983) 605–610.
- [205] K.A. Marks, C.E. Mallard, I. Roberts, C.E. Williams, P.D. Gluckman, A.D. Edwards, Nitric oxide synthase inhibition attenuates delayed vasodilation and increases injury after cerebral ischemia in fetal sheep, *Pediatr. Res.* 40 (1996) 185–191.
- [206] T.A. Marshall, F. Marshall, P.P. Reddy, Physiologic changes associated with ligation of the ductus arteriosus in preterm fetuses, *J. Pediatr.* 101 (1982) 749–753.
- [207] D. Martin, N. Chinookoswong, G. Miller, The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia/ischemia, *Exp. Neurol.* 130 (1994) 362–367.
- [208] L.J. Martin, C.D. Blackstone, A.I. Levey, R.L. Huganir, D.L. Price, AMPA glutamate receptor subunits are differentially distributed in rat, *Brain Neurosci.* 53 (1993) 327–358.
- [209] D. Martz, G. Rayos, G.P. Schielke, A.L. Betz, Allopurinol and dimethylthiourea reduce brain infarction following middle cerebral artery occlusion in rats, *Stroke* 20 (1989) 488–494.
- [210] Y. Matsuo, H. Onodera, Y. Shiga, M. Nakamura, M. Ninomya, T. Kihara, K. Kogure, Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion, *Stroke* 25 (1994) 1469–1475.
- [211] J.M. McCord, Oxygen-derived free radicals in postischemic tissue injury, *N. Engl. J. Med.* 312 (1985) 159–163.
- [212] J.W. McDonald, F.S. Silverstein, M.W. Johnson, MK-801 protects the neonatal brain from hypoxic/ischemic damage, *Eur. J. Pharmacol.* 140 (1987) 359–361.
- [213] T.K. McIntosh, R. Vink, I. Yamakami, A.I. Faden, Magnesium protects against neurological deficit after brain injury, *Brain Res.* 482 (1989) 252–260.
- [214] J.P. McManus, A.M. Buchan, I.E. Hill, I. Rasquinha, E. Preston, Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain, *Neurosci. Lett.* 164 (1993) 89–92.
- [215] A. McRae, E. Gilland, E. Bona, H. Hagberg, Microglia activation after neonatal hypoxia–ischemia, *Dev. Brain Res.* 84 (1995) 245–252.
- [216] H. Mehmet, X. Yue, M.V. Squier, A. Lorek, E. Cady, J. Penrice, C. Sarraf, M. Wylezinska, V. Kirkbridge, C. Cooper, G.C. Brown, J.S. Wyatt, E.O.R. Reynolds, A.D. Edwards, Increased apoptosis in the cingulate sulcus of newborn piglets following transient hypoxia–ischemia is related to the degree of high energy phosphate depletion during the insult, *Neurosci. Lett.* 181 (1994) 121–125.
- [217] B. Meldrum, Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters, *Clin. Sci.* 68 (1985) 113–122.
- [218] A.C. Mello Filho, M.E. Hoffman, R. Meneghini, Cell killing and DNA damage by hydrogen peroxide are mediated by intracellular iron, *J. Biochem.* 218 (1984) 273–275.
- [219] J.D. Michenfelder, R.A. Theye, Hypothermia: effect on canine brain and whole body metabolism, *Anesthesiology* 29 (1968) 1107–1112.
- [220] J.D. Michenfelder, R.A. Theye, The effects of anesthesia and hypothermia on canine cerebral ATP and lactate during anoxia produced by decapitation, *Anesthesiology* 33 (1970) 430–439.
- [221] D.W. Milligran, Failure of autoregulation and intraventricular haemorrhage in preterm infants, *Lancet* 1 (1980) 896–898.
- [222] M. Minami, Y. Kurashi, K. Yabuuchi, A. Yamazaki, M. Satoh, Induction of interleukin-1 $\beta$  mRNA in rat brain after transient forebrain ischemia, *J. Neurochem.* 58 (1992) 390–392.

- [223] R.B. Mink, A.J. Dutka, J.M. Hallenbeck, Allopurinol pretreatment improves evoked response recovery following global cerebral ischemia in dogs, *Stroke* 22 (1991) 660–665.
- [224] O.P. Mishra, M. Delivoria-Papadopoulos, Lipid peroxidation in developing fetal guinea pig brain during normoxia and hypoxia, *Dev. Brain Res.* 45 (1989) 129–135.
- [225] A. Mitani, Y. Andou, K. Kataoka, Selective vulnerability of hippocampal CA 1 neurons cannot be explained in terms of an increase in glutamate concentration during ischemia in the gerbil brain, *Neuroscience* 48 (1992) 307–313.
- [226] R. Mittendorf, R. Covert, J. Boman, B. Khoshnood, K.-S. Lee, M. Siegler, Is tokolytic magnesium sulphate associated with increased total paediatric mortality?, *Lancet* 350 (1997) 1517–1518.
- [227] T. Miyashita, M. Harigai, M. Hanada, J. Reed, Identification of a p53 dependent negative response element in the *bcl-2* gene, *Cancer Res.* 54 (1994) 3131–3155.
- [228] T. Miyashita, S. Krajewski, M. Krajewski, H. Wang, H. Lin, D. Liebermann, B. Hoffmann, J. Reed, Tumor suppressor p53 is a regulator of *bcl-2* and *bax* gene expression in vitro and in vivo, *Oncogene* 9 (1994) 1799–1805.
- [229] T. Miyashita, J. Reed, Tumor suppressor p53 is a direct transcriptional activator of the human *bax* gene, *Cell* 80 (1995) 293–299.
- [230] D.T. Monaghan, R.J. Bridges, C.W. Cotman, The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system, *Annu. Rev. Pharmacol. Toxicol.* 29 (1989) 365–402.
- [231] D.M. Moody, W.R. Brown, V.R. Challa, S.M. Block, Alkaline phosphatase histochemical staining in the study of germinal matrix hemorrhage and brain vascular morphology in a very low birth-weight neonate, *Pediatr. Res.* 35 (1994) 424–430.
- [232] T. Morioka, A.N. Kalebica, W.J. Streit, Progressive expression of immunomolecules on microglial cells in rat dorsal hippocampus following transient forebrain ischemia, *Acta Neuropathol.* 83 (1992) 149–157.
- [233] F. Munell, R.E. Burke, A. Bandele, R.M. Gubits, Localization of *c-fos*, *c-jun*, and *hsp70* mRNA expression in brain after neonatal hypoxia–ischemia, *Dev. Brain Res.* 77 (1994) 111–121.
- [234] T. Nagafuji, M. Sugiyama, T. Matsui, T. Koide, A narrow therapeutic window of a nitric oxide synthase inhibitor against transient ischemic brain injury, *Eur. J. Pharmacol.* 248 (1993) 325–328.
- [235] Y. Nakamura, T. Okudera, S. Fukuda, T. Hashimoto, Germinal matrix hemorrhage of venous origin in preterm neonates, *Hum. Pathol.* 21 (1990) 1059–1062.
- [236] C.F. Nathan, Nitric oxide as secretory product of mammalian cells, *FASEB J.* 6 (1992) 3051–3064.
- [237] J. Negrin, Selective local hypothermia in neurosurgery, *N.Y. State J. Med.* 61 (1961) 2951–2965.
- [238] K.B. Nelson, J.K. Gretherm, Can magnesium sulfate reduce the risk of cerebral palsy in very low birth-weight infants?, *Pediatrics* 95 (1995) 263–269.
- [239] F. Nicoletti, J.T. Wroblewski, A. Novelli, H. Alho, A. Guidotti, E. Costa, The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells, *J. Neurosci.* 6 (1986) 1905–1911.
- [240] T. Nishikawa, J.R. Kirsch, R.C. Koehler, D.S. Bredt, S.H. Snyder, R.J. Traystman, Effect of nitric oxide synthase inhibition on cerebral blood flow and injury volume during focal ischemia in cats, *Stroke* 24 (1993) 1717–1724.
- [241] M.G. Norman, Perinatal brain damage, *Perspect. Pediatr. Pathol.* 4 (1978) 41–92.
- [242] M.G. Norman, The pathology of perinatal asphyxia, *Can. Med. Assoc. J. (Suppl.)* 1988, pp. 15–20.
- [243] M.G. Norman, McGillivray, Fetal neuropathology of proliferative vasculopathy and hydranencephaly–hydrocephaly with multiple limb pterygia, *Pediatr. Neurosci.* 14 (1988) 301–306.
- [244] L. Nowak, P. Bregestovski, P. Ascher, A. Herbet, A. Prochiantz, Magnesium gates glutamate-activated channels in mouse central neurones, *Nature* 307 (1984) 462–465.
- [245] J.P. Nowicki, D. Duval, H. Poignet, B. Scatton, Nitric oxide mediates neuronal cell death after focal ischemia in the mouse, *Eur. J. Pharmacol.* 204 (1991) 339–340.
- [246] K. Nozaki, M.F. Beal, Neuroprotection effects of L-kynurenine on hypoxic–ischemic and NMDA lesions in neonatal rats, *J. Cereb. Blood Flow Metab.* 12 (1992) 400–407.
- [247] K. Nozaki, S.P. Finkelstein, M.F. Beal, Basic fibroblast growth factor protect against hypoxia/ischemia in neonatal rats, *J. Cereb. Blood Flow Metab.* 13 (1993) 221–228.
- [248] T.P. Obrenovitch, J. Urenjak, E. Zilkha, Excitotoxicity in cerebral ischemia: alternative hypothesis to high extracellular glutamate, in: J. Kriegstein (Ed.), *Pharmacology of Cerebral Ischemia*, Medpharm Scientific Publishers, Stuttgart, 1996, 9 pp.
- [249] B. Ohrt, R. Riegel, D. Wolke, Langzeitprognose sehr kleiner Frühgeborener, *Arch. Gynecol. Obstet.* 257 (1995) 480–492.
- [250] J. Oillet, V. Koziel, P. Vert, J.-L. Daval, Influence of post-hypoxia reoxygenation conditions on energy metabolism and superoxide production in cultured neurons from the rat forebrain, *Pediatr. Res.* 39 (1996) 598–603.
- [251] Y. Okada, B.R. Copeland, E. Mori, M.M. Tung, W.S. Thomas, G.J. del Zoppo, P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion, *Stroke* 25 (1994) 202–211.
- [252] J.W. Olney, Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate, *Science* 164 (1969) 719–721.
- [253] J.W. Olney, L.G. Sharpe, R.D. Feigin, Glutamate-induced brain damage in infant primates, *J. Neuropathol. Exp. Neurol.* 31 (1972) 464–488.
- [254] J.W. Olney, J.L. Ikonomidou, J.L. Mosinger, G. Friedrich, MK-801 prevents hypobaric–ischemic neuronal degeneration in infant rat brain, *J. Neurosci.* 9 (1989) 1701–1704.
- [255] J.M. Palacios, D.L. Niehoff, M.J. Kuhar, Ontogeny of GABA and benzodiazepine receptors: effects of Triton X-100-bromide and muscimol, *Brain Res.* 179 (1979) 390–395.
- [256] C. Palmer, R.C. Vannucci, J. Towfighi, Reduction of perinatal hypoxic–ischemic brain damage with allopurinol, *Pediatr. Res.* 27 (1990) 332–336.
- [257] C. Palmer, J. Towfighi, R.L. Roberts, D.F. Heitjan, Allopurinol administered after inducing hypoxia/ischemia reduces brain injury in 7-days-old rats, *Pediatr. Res.* 33 (1993) 405–411.
- [258] C. Palmer, R.L. Roberts, C. Bero, Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats, *Stroke* 25 (1994) 1039–1045.
- [259] C. Palmer, Hypoxic–ischemic encephalopathy. Therapeutic approaches against microvascular injury, and the role of neutrophils, PAF, and free radicals, *Clin. Perinatol.* 22 (1995) 481–517.
- [260] C. Palmer, R.L. Roberts, P.I. Young, Neutropenia before but not after hypoxia/ischemia reduces brain injury in neonatal rats, *J. Cereb. Blood Flow Metab.* 15 (1995) 291.
- [261] N. Paneth, R. Rudelli, W. Monte, E. Rodriguez, J. Pinto, R. Kairam, E. Kazam, White matter necrosis in very low birth weight infants: neuropathologic and ultrasonographic findings in infants surviving six days or longer, *J. Pediatr.* 116 (1990) 975–984.
- [262] K.E. Pape, J.S. Wigglesworth, Haemorrhage, ischaemia and the perinatal brain, JB Lippincott, Philadelphia, 1979.
- [263] C.K. Park, D.G. Nehls, G.M. Teasdale, J. McCulloch, The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat, *Ann. Neurol.* 24 (1988) 543–551.
- [264] J. Parkhouse, General anesthesia as an aid to therapeutic hypothermia, *Br. Med. J.* 2 (1957) 751.
- [265] W. Paschen, Disturbances of calcium homeostasis within the endoplasmic reticulum may contribute to the development of ischemic-cell damage, *Med. Hypotheses* 47 (1996) 283–288.

- [266] W. Paschen, J. Doutheil, C. Gissel, M. Treiman, Depletion of neuronal endoplasmic reticulum calcium stores by thapsigargin: effect on protein synthesis, *J. Neurochem.* 67 (1996) 1735–1743.
- [267] A. Patt, I.R. Horeh, E.M. Berger, A.H. Harken, J.E. Repine, Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains, *J. Pediatr. Surg.* 25 (1990) 224–228.
- [268] R.M. Patten, L.A. Mack, D.A. Nyberg, R.A. Filly, Twin embolization syndrome: prenatal sonographic detection and significance, *Radiology* 173 (1989) 685–689.
- [269] J. Penrice, A. Lorek, E.B. Cady, P.N. Amess, M. Wylenezinska, C.E. Cooper, P. D'Souza, G.C. Brown, V. Kirkbridge, A.D. Edwards, Wyatt, E.O.R. Reynolds, Proton magnetic resonance spectroscopy of the brain during acute hypoxia-ischemia and delayed cerebral energy failure in the newborn piglet, *Pediatr. Res.* 41 (1997) 795–802.
- [270] G. Perides, F.E. Jensen, P. Edgecomb, D.C. Rueger, M.E. Charnes, Neuroprotective effect of human osteogenic protein-1 in a rat model of cerebral hypoxia ischemia, *Neurosci. Lett.* 187 (1995) 21–24.
- [271] O. Pryds, G. Greisen, H. Lou, B. Friis-Hansen, Vasoparalysis associated with brain damage in asphyxiated term infants, *J. Pediatr.* 117 (1990) 119–125.
- [272] M.J. Quast, J. Wei, N.C. Huang, Nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester decreases ischemic damage in reversible focal ischemia in hyperglycemic rats, *Brain Res.* 677 (1995) 204–212.
- [273] Z. Ram, M. Sadeh, I. Shacked, A. Sahar, M. Hadani, Magnesium sulfate reverses experimental delayed cerebral vasospasm after subarachnoid hemorrhage in rats, *Stroke* 22 (1991) 922–927.
- [274] R.R. Ratan, T.H. Murphy, J.M. Barban, Oxidative stress induces apoptosis in embryonic cortical neurons, *J. Neurochem.* 62 (1994) 376–379.
- [275] J. Reed, Bcl-2 and the regulation of programmed cell death, *J. Cell Biol.* 124 (1994) 1–2.
- [276] M. Reivich, A.W. Brann, Jr., H.M. Shapiro, Regional cerebral blood flow during prolonged partial asphyxia, in: J.S. Meyer, M. Reivich, H. Lechner (Eds.), *Research on the Cerebral Circulation*, Thomas, Springfield, IL, 1972.
- [277] U. Roessmann, P. Gambetti, Pathological reaction of astrocytes in perinatal brain injury. Immunohistochemical study, *Acta Neuropathol. (Berlin)* 70 (1986) 302–307.
- [278] J.L. Romson, B.G. Hook, S.L. Kunkel, G.D. Abrams, M.A. Schork, B.R. Lucchesi, Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog, *Circulation* 67 (1983) 1016–1023.
- [279] L.B. Rorke, *Pathology of Perinatal Brain Injury*, Raven Press, New York, 1982.
- [280] L.B. Rorke, Anatomical features of the developing brain implicated in pathogenesis of hypoxic-ischemic injury, *Brain Pathol.* 2 (1992) 211–221.
- [281] D.M. Rosenbaum, M. Michaelson, D.K. Batter, P. Doshi, J.A. Kessler, Evidence for hypoxia-induced, programmed cell death of cultured neurons, *Ann. Neurol.* 36 (1994) 864–870.
- [282] A.A. Rosenberg, Cerebral blood flow and O<sub>2</sub> metabolism after asphyxia in neonatal lambs, *Pediatr. Res.* 20 (1986) 778–782.
- [283] A.A. Rosenberg, E. Murdaugh, C.W. White, The role of oxygen free radicals in postasphyxia cerebral hypoperfusion in newborn lambs, *Pediatr. Res.* 26 (1989) 215–219.
- [284] S.M. Rothman, Synaptic activity mediates death of hypoxic neurons, *Science* 220 (1983) 536–537.
- [285] S.M. Rothman, Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death, *J. Neurosci.* 4 (1984) 1884–1891.
- [286] S.M. Rothman, J.W. Olney, Glutamate and the pathophysiology of hypoxic-ischemic brain damage, *Ann. Neurol.* 19 (1986) 105–111.
- [287] S.M. Rothman, Synaptic activity mediates death by hypoxic neurons, *Science* 220 (1989) 536–537.
- [288] N.J. Rothwell, S.J. Hopkins, Cytokines and the nervous system. II. Actions and mechanisms of action, *Trends Neurol. Sci.* 18 (1995) 130–136.
- [289] A.M. Rudolph, M.A. Heymann, Cardiac output in the fetal lamb: the effects of spontaneous and induced changes of heart rate on right and left ventricular output, *Am. J. Obstet. Gynaecol.* 124 (1976) 183–192.
- [290] S. Sakhi, A. Bruce, N. Sun, G. Tocco, M. Baudry, S. Schreiber, p53 induction is associated with neuronal damage in the central nervous system, *Proc. Natl. Acad. Sci.* 91 (1994) 7525–7529.
- [291] J.M. Scheller, K.B. Nelson, Twinning and neurologic morbidity, *Am. J. Dis. Child.* 146 (1992) 1110–1113.
- [292] D.E. Schendel, C.J. Berg, M. Yeargin-Allsopp, C.A. Boyle, P. Decoufle, Prenatal magnesium sulfate exposure and risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years, *JAMA* 276 (1996) 1805–1810.
- [293] H. Schmid-Schönbein, Microrheology of erythrocytes and thrombocytes, blood viscosity and the distribution of blood flow in the microcirculation, in: H.W. Altmann, F. Büchner, H. Cottier (Eds.), *Handbuch der Allgemeinen Pathologie III/7: Mikrozirkulation*, Springer, Berlin, 1977, 289 pp.
- [294] R. Schoepfer, H. Monyer, B. Sommer, W. Wisden, R. Sprengel, T. Kuner, H. Lomeli, A. Herb, M. Kohler, N. Burnashev, W. Gunther, P. Ruppersberg, P. Seeburg, Molecular biology of glutamate receptors, *Prog. Neurobiol.* 42 (1994) 353–357.
- [295] C.B. Sedzimir, Therapeutic hypothermia in cases of head injury, *J. Neurosurg.* 16 (1959) 407–414.
- [296] J.M. Seelig, E.P. Wei, H. Kontos, Effect of changes in magnesium ion concentration on cat cerebral arterioles, *Am. J. Physiol.* 245 (1983) H22–H26.
- [297] S. Shapira, T. Kadar, B.A. Weissman, Dose-dependent effect of nitric oxide synthase inhibition following transient forebrain ischemia in gerbils, *Brain Res.* 668 (1994) 80–84.
- [298] M.I. Shevell, K. Silver, A.M. O'Gorman, G.V. Watters, J.L. Montes, Neonatal dural sinus thrombosis, *Pediatr. Neurol.* 5 (1989) 161–165.
- [299] A. Shirahata, T. Nakamura, M. Shimono, M. Kaneko, S. Tanaka, Blood coagulation findings and the efficacy of factor XIII concentrate in premature infants with intracranial hemorrhages, *Thromb. Res.* 57 (1990) 755–763.
- [300] M. Shivji, M. Kenny, R. Wood, Proliferating cell nuclear antigen is required for DNA excision repair, *Cell* 69 (1992) 367–374.
- [301] B.M. Sibai, J.M. Graham, J.H. McCubbin, A comparison of intravenous and intramuscular magnesium sulfate regimens in preeclampsia, *Am. J. Obstet. Gynecol.* 150 (1984) 728–733.
- [302] E. Siemkowicz, Cerebrovascular resistance in ischemia, *Pflugers Arch.* 388 (1980) 243–247.
- [303] B.K. Siesjö, Cell damage in the brain: a speculative synthesis, *J. Cereb. Blood Flow Metab.* 1 (1981) 155–185.
- [304] B.K. Siesjö, F. Bengtsson, Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis, *J. Cereb. Blood Flow Metab.* 9 (1989) 127–140.
- [305] B.K. Siesjö, K. Katsura, K. Pahlmark, M.-L. Smith, The multiple causes of ischemic brain damage: a speculative synthesis, in: J. Kriegstein, H. Oberpichler-Schwenk (Eds.), *Pharmacology of Cerebral Ischemia*, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1992, 511 pp.
- [306] F.S. Silverstein, K. Buchanan, C. Hudson, M.V. Johnston, Flunarizine limits hypoxia/ischemia induced morphologic injury in immature rat brain, *Stroke* 17 (1986) 477–482.
- [307] M. Smith, I.-T. Cen, Q. Zan, I. Bae, C.-Y. Chen, T. Gilmer, M. Kastan, P. O'Connor, Interaction of the p53 regulated protein Gadd45 with proliferating cell nuclear antigen, *Science* 266 (1994) 1376–1380.
- [308] M.A. Soriano, A. Tortosa, A.M. Planas, E. Rodriguez-Farre, I. Ferrer, Induction of HSP70 mRNA and HSP70 protein in the

- hippocampus of the developing gerbil following transient forebrain ischemia, *Brain Res.* 653 (1994) 191–198.
- [309] H. Spanggord, R.A. Sheldon, D.M. Ferriero, Cysteamine eliminates nitric oxide synthase activity but is not protective to the hypoxic-ischemic neonatal brain, *Neurosci. Lett.* 213 (1996) 41–44.
- [310] E. Streicher, H. Wiesniewski, I. Klatzo, Resistance of immature brain to experimental cerebral edema, *Neurology* 15 (1965) 833.
- [311] L.N. Sutton, B.J. Clark, C.R. Norwood, E.J. Woodford, F.A. Welsh, Global cerebral ischemia in piglets under conditions of mild and deep hypothermia, *Stroke* 22 (1991) 1567–1573.
- [312] J.A. Swain, T.J. McDonald Jr., R.S. Balaban, R.C. Robbins, Metabolism of the heart and brain during hypothermic cardiopulmonary bypass, *Ann. Thorac. Surg.* 51 (1991) 105–109.
- [313] J.W. Swann, R.J. Brady, D.L. Martin, Postnatal development of GABA-mediated synaptic inhibition in rat hippocampus, *Neuroscience* 28 (1989) 551–561.
- [314] M.D. Szabo, G. Crosby, Effect of profound hypermagnesemia on spinal cord glucose utilization in rats, *Stroke* 19 (1988) 747–749.
- [315] W. Szymonowicz, K. Schaffler, L.J. Cussen, V.Y. Yu, Ultrasound and necropsy study of periventricular haemorrhage in preterm infants, *Arch. Dis. Child.* 59 (1984) 637–642.
- [316] W. Szymonowicz, A.M. Walker, V.Y. Yu, M.L. Stewart, J. Cannata, L. Cussen, Regional cerebral blood flow after hemorrhagic hypotension in the preterm, near-term, and newborn lamb, *Pediatr. Res.* 28 (1990) 361–366.
- [317] S. Takagi, L. Cocito, K.-A. Hossmann, Blood recirculation and pharmacological responsiveness of the cerebral vasculature following prolonged ischemia of cat brain, *Stroke* 8 (1977) 707–712.
- [318] S. Takashima, D.L. Armstrong, L.E. Becker, Subcortical leukomalacia. Relationship to development of the cerebral sulcus and its vascular supply, *Arch. Neurol.* 35 (1978) 470–472.
- [319] S. Takashima, Pathology on neonatal hypoxic brain damage and intracranial hemorrhage. Factors important in their pathogenesis, in: Y. Fukuyama, M. Arima, K. Maekawa (Eds.), *International Congress Serie No. 579. Child Neurology*, Excerpta Medica, Amsterdam, 1982.
- [320] W.K.M. Tan, C.E. Williams, A.J. Gunn, C.E. Mallard, P.D. Gluckman, Suppression of postischemic epileptiform activity with MK-801 improves neural outcome in fetal sheep, *Ann. Neurol.* 32 (1992) 677–682.
- [321] W.K.M. Tan, C.E. Williams, A.J. Gunn, C.E. Mallard, P.D. Gluckman, Pretreatment with monosialoganglioside GM1 protects the brain of fetal sheep against hypoxic/ischemic injury without causing systemic compromise, *Pediatr. Res.* 34 (1993) 18–22.
- [322] A.L. Tappel, Lipid peroxidation damage to cell components, *Fed. Proc.* 32 (1973) 1870–1874.
- [323] The Eclampsia Trial Collaborative Group, Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial, *Lancet* 345 (1995) 1455–1463.
- [324] R. Thilmann, Y. Xie, P. Kleihues, M. Kiessling, Persistent inhibition of protein synthesis precedes delayed neuronal death in postischemic gerbil hippocampus, *Acta Neuropathol. (Berlin)* 71 (1986) 88–93.
- [325] S. Timsit, S. Rivera, N.C.A. Louis, E. Tremblay, F. Guischard, P. Ouaghi, Y. Ben-Ari, M. Khrestchatsky, Cyclin D1 is upregulated in regions of neuronal death during ischemia, epilepsy and in a developmental model of neuronal death, *Soc. Neurosci. Abstr.* 22 (1996) 1480.
- [326] G.C. Tombaugh, R.M. Sapolski, Mechanistic distinction between excitotoxic and acidotic hippocampal damage in an in vitro model of ischemia, *J. Cereb. Blood Flow Metab.* 10 (1990) 527–535.
- [327] T. Tominaga, S. Kure, K. Narisawa, T. Yoshimoto, Endonuclease activation following focal ischemic injury in the rat brain, *Brain Res.* 608 (1993) 21–26.
- [328] D.A. Trauner, F.L. Mannino, Neurodevelopmental outcome after neonatal cerebrovascular accident, *J. Pediatr.* 108 (1986) 459–461.
- [329] R.J. Traystman, J.R. Kirsch, R.C. Koehler, Oxygen radical mechanisms of brain injury following ischemia and reperfusion, *J. Appl. Physiol.* 71 (1991) 1185–1195.
- [330] R.R. Trifiletti, Neuroprotective effects of NG-nitro-L-arginine in focal stroke in the 7-day old rat, *Eur. J. Pharmacol.* 218 (1992) 197–198.
- [331] J.Q. Trounce, M.I. Levene, Diagnosis and outcome of subcortical cystic leukomalacia, *Arch. Dis. Child.* 60 (1985) 1041–1044.
- [332] T. Tsuda, K. Kogure, K. Nishioka, T. Watanabe,  $Mg^{2+}$  administered up to twenty-four hours following reperfusion prevents ischemic damage of the CA1 neurons in the rat hippocampus, *Neuroscience* 44 (1991) 335–341.
- [333] U.I. Tuor, M.R. del Bigio, Protection against hypoxic/ischemic damage with corticosterone and dexamethasone: inhibition by glucocorticoid antagonist, *J. Cereb. Blood Flow Metab.* 15 (Suppl. 1) (1995) 279.
- [334] U.I. Tuor, P.D. Chumas, M.R. Del Bigio, Prevention of hypoxic/ischemic damage with dexamethasone is dependent on age and not influenced by fasting, *Exp. Neurol.* 132 (1995) 116–122.
- [335] U.I. Tuor, M.R. del Bigio, P.D. Chumas, Brain damage due to cerebral hypoxia/ischemia in the neonate: pathology and pharmacological modification, *Cerebrovasc. Brain Metab. Rev.* 8 (1996) 159–193.
- [336] D. Uematsu, J.H. Greenberg, N. Araki, M. Reivich, Mechanisms underlying protective effects of MK-801 against NMDA-induced neuronal injury in vivo, *J. Cereb. Blood Flow Metab.* 11 (1991) 779–785.
- [337] R.C. Vannucci, Experimental biology of cerebral hypoxia-ischemia: relation to perinatal brain damage, *Pediatr. Res.* 27 (1990) 317–326.
- [338] N.B. Vedder, R.K. Winn, C.L. Rice, E.Y. Chi, K.E. Arfors, J.M. Harlan, A monoclonal antibody to adherence promoting leukocyte glycoprotein, CD 18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits, *J. Clin. Invest.* 81 (1988) 939–944.
- [339] J.J. Volpe, *Neurology of the Newborn*, Saunders, Philadelphia, 1995.
- [340] U.H. von Andrian, J.D. Chambers, L.M. McEvoy, R.F. Bargatze, K.E. Arfors, E.C. Butcher, Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte  $\beta 2$  integrins in vivo, *Proc. Natl. Acad. Sci. U.S.A.* 88 (1991) 7538–7542.
- [341] S. Waga, G. Hannon, D. Beach, B. Stillman, The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA, *Nature* 369 (1994) 574–578.
- [342] J. Ward, W. Blakely, E. Joner, Mammalian cells are not killed by DNA strand breaks caused by hydroxyl radicals from hydrogen peroxide, *Radiat. Res.* 103 (1995) 383–392.
- [343] C.G. Wasterlain, L.M. Adams, P.H. Schwartz, H. Hattori, R.D. Sofia, J.K. Wichman, Posthypoxic treatment with felbamate is neuroprotective in a rat model of hypoxia/ischemia, *Neurology* 43 (1993) 2303–2310.
- [344] M.A. Warner, K.H. Neill, J.V. Nadler, B.J. Crain, Regionally selective effects of NMDA receptor antagonists against ischemic brain damage in the gerbil, *J. Cereb. Blood Flow Metab.* 11 (1991) 600–610.
- [345] F.A. Welsh, R.E. Sims, V.A. Harris, Mild hypothermia prevents ischemic injury in gerbil hippocampus, *J. Cereb. Blood Flow Metab.* 10 (1990) 557–563.
- [346] B. Westin, J.A. Miller, R. Nyberg, E. Wendenberg, Neonatal asphyxia pallida treated with hypothermia alone or with hypothermia and transfusion of oxygenated blood, *Surgery* 45 (1959) 868–879.
- [347] R. Widmann, T. Kuroiwa, P. Bonnekok, K.-A. Hossmann, [ $^{14}C$ ] Leucine incorporation into proteins in gerbils after transient ischemia: relationship to selective vulnerability of hippocampus, *J. Neurochem.* 56 (1991) 789–796.

- [348] R. Widmann, T. Miyazawa, K.-A. Hossmann, Protective effect of hypothermia on hippocampal injury after 30 min of forebrain ischemia in rats is mediated by postischemic recovery of protein synthesis, *J. Neurochem.* 61 (1993) 200–209.
- [349] C. Wiessner, I. Brinck, P. Lorenz, T. Neumann-Haefelin, P. Vogel, K. Yamashita, Cyclin D1 messenger RNA is induced in microglia rather than neurons following transient forebrain ischemia, *Neuroscience* 72 (1996) 947–958.
- [350] C.E. Williams, A.J. Gunn, P.D. Gluckman, Time course of intracellular edema and epileptiform activity following prenatal cerebral ischemia in sheep, *Stroke* 22 (1991) 516–521.
- [351] C.E. Williams, A.J. Gunn, C. Mallard, P.D. Gluckman, Outcome after ischemia in the developing sheep brain: an electroencephalographic and histological study, *Ann. Neurol.* 31 (1992) 14–21.
- [352] Y. Xie, K. Seo, K.-A. Hossmann, Effect of barbiturate treatment on post-ischemic protein biosynthesis in gerbil brain, *J. Neurol. Sci.* 92 (1989) 317–328.
- [353] K. Yamashita, Y. Eguchi, K. Kajiwara, H. Ito, Mild hypothermia ameliorates ubiquitin synthesis and prevents delayed neuronal death in the gerbil hippocampus, *Stroke* 22 (1991) 1574–1581.
- [354] H. Yoon, C.J. Kim, R. Romero, J.K. Jun, K.H. Park, S.T. Choi, J.G. Chi, Experimentally induced intrauterine infection causes fetal brain white matter lesions in rabbits, *Am. J. Obstet. Gynecol.* 177 (1997) 797–802.
- [355] N. Yoshida, D.N. Granger, D.C. Anderson, R. Rothlein, C. Lane, P.R. Kvietys, Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells, *Am. J. Physiol.* 262 (1992) H1891–H1898.
- [356] H. Yoshioka, Y. Kadomoto, M. Mino, Y. Morikawa, Y. Kasubuchi, T. Kusunoki, Multicystic encephalomalacia in liveborn twin with a stillborn macerated co-twin, *J. Pediatr.* 95 (1979) 798–800.
- [357] F. Zhang, S. Xu, C. Iadecola, Time dependence of effect of nitric oxide synthase inhibition on cerebral ischemic injury, *J. Cereb. Blood. Flow Metab.* 15 (1994) 595–601.
- [358] F. Zhang, R.M. Casey, M.E. Ross, C. Iadecola, Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion, *Stroke* 27 (1996) 317–323.